

Table of Contents

C4591001 BIMO Investigator Report	3
C4591001 Investigator Curriculum Vitae (CV)	42
Argentina	42
Brazil	43
Germany	46
South Africa	52
Turkey	58
United States	88
BNT162-01 BIMO Investigator Report	258
BNT162-01 Investigator Curriculum Vitae (CV)	259
276-01 - Schultz	259
276-02 - Baumann	261
276-03 - Halabi	264
276-04 - Blank	266
276-05 - Vehreschild	269

090177e1968ea843\Final\Final On: 18-Mar-2021 14:01 (GMT)

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
1001	Mark Mulligan	NYU Langone Health Schwartz Health Care Center 530 First Ave, 12th Fl New York, NEW YORK 10016 UNITED STATES	Phone: (212) 263-9410 Email: mark.mulligan@nyulangone.org Fax:
1002	Kathleen Neuzil	University of Maryland, Center for Vaccine Development and Global Health 685 W. Baltimore St., HSF I, 4th Fl Baltimore, MARYLAND 21201 UNITED STATES	Phone: 410-706-5328 Email: kneuzil@som.umaryland.edu Fax: 4107066205
1003	Edward Walsh	Rochester Regional Health/Rochester General Hospital Infectious Disease Dept. 1425 Portland Ave Rochester, NY 14621 UNITED STATES	Phone: 585-922-5944 Email: edward.walsh@rochesterregional.org Fax:
1005	Matthew Davis	Rochester Clinical Research, Inc. 500 Helendale Rd, Ste 265 Rochester, NEW YORK 14609 UNITED STATES	Phone: (585)-288-0890 Email: mdavis@rcrclinical.com Fax: 5852880893
1005	Matthew Davis	Rochester Clinical Research, Inc. 500 Helendale Rd, L20 Rochester, NY 14609	Phone: (585)-288-0890 Email: mdavis@rcrclinical.com Fax: 5852880893

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		UNITED STATES	
1006	James Peterson	J. Lewis Research, Inc. / Foothill Family Clinic 2295 Foothill Dr Salt Lake City, UT 84109 UNITED STATES	Phone: 801.486.3021 ext. 3370 Email: jpeterson@jlewisresearch.com Fax:
1007	Robert Frenck	Cincinnati Children's Hospital Medical Center Cincinnati Center for Clinical Research (CCCR) 619 Oak St Cincinnati, OH 45206 UNITED STATES	Phone: 5136364463 Email: robert.frenck@cchmc.org Fax: 5136367039
1007	Robert Frenck	Cincinnati Children's Hospital Medical Center Gamble Program for Clinical Studies 3333 Burnet Ave, MLC 6014 Cincinnati, OH 45229-3039 UNITED STATES	Phone: 5136364463 Email: robert.frenck@cchmc.org Fax: 5136367039
1008	Timothy Jennings	Clinical Research Professionals 17998 Chesterfield Airport Rd, Ste 100 Chesterfield, MO 63005 UNITED STATES	Phone: 6362201200 Email: tjennings@clinicalresearchprofessionals.net Fax: 3146673331
1009	Shane Christensen	J. Lewis Research, Inc. / Foothill Family Clinic South 6360 S 3000 E, Ste 100	Phone: (801) 554-0158 Email: schristensen@jlewisresearch.com

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Salt Lake City, UT 84121 UNITED STATES	Fax: 8017337063
1011	Susann Varano	Clinical Research Consulting, LLC 2080 Bridgeport Ave Milford, CT 06460 UNITED STATES	Phone: 2033863115 Email: svarano@clinicalrc.com Fax: 2038780732
1012	Matthew Doust	HOPE Research Institute 3900 E. Camelback Rd, Ste 125, 130 & 135 Phoenix, AZ 85018 UNITED STATES	Phone: (602)-288-4673 Email: matthew.doust@hriaz.com Fax: 6022884678
1012	Matthew Doust	The Pain Center of Arizona 3900 E. Camelback Rd, Ste 190 Phoenix, AZ 85018 UNITED STATES	Phone: (602)-288-4673 Email: matthew.doust@hriaz.com Fax: 6022884678
1013	Michael Dever	Clinical Neuroscience Solutions, Inc 618 E. S St, Ste 100 Orlando, FL 32801 UNITED STATES	Phone: (407)-425-5100 Email: mdever@cnshealthcare.com Fax: 4074253009
1015	Elizabeth Barnett	Boston Medical Center 1 Boston Medical Center Pl., Shapiro Bldg. 9th Fl.	Phone: (617) 414-3623 Email: ebarnett@bu.edu Fax: 6174147230

090177e1968ea843\Final\Final On: 18-Mar-2021 14:01 (GMT)

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
1016	Daniel Finn	Boston, MA 02118 UNITED STATES Kentucky Pediatric/ Adult Research 201 S 5th St Bardstown, KENTUCKY 40004 UNITED STATES	Phone: (502)-349-1569 Email: (b) (6) Fax: 5023490286
1018	Veronica Fragoso	Texas Center for Drug Development, Inc. 6550 Mapleridge St, Ste 201, 206, 216, 220 Houston, TEXAS 77081 UNITED STATES	Phone: 7138382022 Email: veronica.fragoso@tcddresearch.com Fax: 7138382023
1019	Charles Andrews	Diagnostics Research Group 4410 Medical Dr, Ste 360 San Antonio, TEXAS 78229 UNITED STATES	Phone: 210-692-7157 Email: dr.andrews@dxrg.com Fax: 2106921999
1021	John Rubino	PMG Research of Raleigh, LLC 3521 Haworth Dr, Ste 100 Raleigh, NC 27609 UNITED STATES	Phone: 9197834895 Email: jrubino@raleighmedicalgroup.com Fax: 9197834894
1022	Steven Kaster	Wenatchee Valley Hospital Clinical Research Department 820 N Chelan Ave	Phone: 509-436-4050 Email: steven.kaster@confluencehealth

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Wenatchee, WA 98801 UNITED STATES	.org Fax: 5096647177
1024	Christopher Lucasti	South Jersey Infectious Disease 730 Shore Rd Somers Point, NJ 08244 UNITED STATES	Phone: 6099276662 Email: (b) (6) Fax: 6099272942
1027	Alexander Murray	PharmQuest 806 Green Valley Rd, Ste 305 Greensboro, NC 27408 UNITED STATES	Phone: (336)-574-8020 Email: amurray@pharmquest.biz Fax: 3365748022
1028	Michael Lillestol	Lillestol Research LLC 4450 31st Ave S, Ste 101 Fargo, ND 58104 UNITED STATES	Phone: +1(701)-232-7705 Email: lillestolmd@lillestolresearch.com Fax: 7018939046
1030	Robert Salata	University Hospitals Cleveland Medical Center 11100 Euclid Ave Cleveland, OH 44106 UNITED STATES	Phone: (216) 844-3293 Email: robert.salata@uhhospitals.org Fax: 2168443145
1036	Marcus Lee	Trinity Clinical Research 709 NW Atlantic St	Phone: 9314340002 Email: (b) (6) Fax:

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
1037	Lisa Usdan	Tullahoma, TN 37388 UNITED STATES Clinical Neuroscience Solutions, Inc. 6401 Poplar Ave, Ste 420 Memphis, TN 38119 UNITED STATES	Phone: (901)-843-1045 Email: lusdan@cnshealthcare.com Fax:
1038	Rick Whiles	Holston Medical Group 240 Medical Park Blvd, Ste 2600 Bristol, TN 37620 UNITED STATES	Phone: 4239902478 Email: rick.whiles@myhmg.com Fax: 4239902496
1039	Gretchen Crook	ARC Clinical Research at Wilson Parke 11714 Wilson Parke Ave., Ste 150 Austin, TX 78726 UNITED STATES	Phone: 737-247-7240 Email: gcrook@arcmd.com Fax: 7372477242
1042	William Seger	Benchmark Research 4504 Boat Club Rd, Ste #400A Fort Worth, TX 76135 UNITED STATES	Phone: (817)-238-7254 Email: williamseger@benchmarkresearch.net Fax:
1042	William Seger	Texas Health Family Care 4504 Boat Club Rd, Ste 800	Phone: (817)-238-7254 Email: williamseger@benchmarkresearch.net

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Fort Worth, TX 76135 UNITED STATES	ch.net Fax:
1044	Aaron Hartman	Virginia Research Center LLC 13911 St. Francis Blvd., Ste 101 Midlothian, VA 23114 UNITED STATES	Phone: 804-893-2273 Email: ahartman@virginiaresearchcent er.com Fax:
1046	Ernest Hendrix	North Alabama Research Center, LLC 721 W Market St, Ste B Athens, AL 35611 UNITED STATES	Phone: 2567719919 Email: ehendrixmd@northalabamarese arch.com Fax: 2567712026
1047	James McMurray	Medical Affiliated Research Center 303 Williams Ave, Ste 511 Huntsville, AL 35801 UNITED STATES	Phone: (256)-533-6603 Email: jgm@marc- research.com Fax:
1048	Abram Burgher	HOPE Research Institute 2525 W. Greenway Rd, Ste 220 Phoenix, AZ 85023 UNITED STATES	Phone: (602)-288-4673 Email: abram.burgher@hriaz.com Fax:
1048	Abram Burgher	HOPE Research Institute 2525 W. Greenway Rd, Ste 250	Phone: (602)-288-4673 Email: abram.burgher@hriaz.com

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Phoenix, AZ 85023 UNITED STATES	Fax:
1052	Suzanne Fussell	Long Beach Clinical Trials Services Inc. 2403 Atlantic Ave Long Beach, CA 90806 UNITED STATES	Phone: (562)-997-3869 Email: sfussell@lbclinicaltrials.com Fax: 5629973082
1054	Mark Leibowitz	National Research Institute 2010 Wilshire Blvd., Ste 302 and 809 Los Angeles, CA 90057 UNITED STATES	Phone: (213)-413-2500 Email: mark.leibowitz@nritrials.com Fax: 2134831494
1055	Helen Stacey	Diablo Clinical Research, Inc. 2255 Ygnacio Valley Rd, Ste M Walnut Creek, CA 94598 UNITED STATES	Phone: (925)-930-7267 Email: hstacey@diabloclinical.com Fax: 9259307392
1056	Jose Cardona	Indago Research & Health Center, Inc. 3700 W 12th Ave, Ste 300 Hialeah, FL 33012 UNITED STATES	Phone: (305)-825-6588 Email: jcardona@indagoresearch.org Fax: 3058256598
1057	Fadi Chalhoub	Clinical Neuroscience Solutions, Inc. 5200 Belfort Rd, Ste 420	Phone: (904)-281-5757 Email: fchalhoub@cnshealthcare.com

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
1066	David Butuk	Jacksonville, FL 32256 UNITED STATES Solaris Clinical Research 1525 E Leigh Field Dr, # 100 Meridian, ID 83646 UNITED STATES	Fax: Phone: 2082880123 Email: pi@solarisclinicalresearch.com Fax:
1068	Andrew Gentry	Bozeman Health Deaconess Hospital dba Bozeman Health Clinical Research 915 Highland Blvd Bozeman, MT 59715 UNITED STATES	Phone: 14064144475 Email: investigator@bozemanhealth.or g Fax: 4064144499
1071	Michael Dunn	Quality Clinical Research, Inc. 10040 Regency Cr, Ste 375 Omaha, NEBRASKA 68114 UNITED STATES	Phone: (402) 934-0044 Email: dunn@qcromaha.com Fax:
1072	Randle Middleton	Optimal Research, LLC 2089 Cecil Ashburn Dr, Ste 203 Huntsville, AL 35802 UNITED STATES	Phone: 2568835635 Email: rmiddleton@optimalsites.net Fax: 2568835636
1073	Corey Anderson	Alliance for Multispecialty Research, LLC	Phone: (602)-910-3343 Email:

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		1492 S Mill Ave, Ste 312 Tempe, ARIZONA 85281 UNITED STATES	corey.anderson@amrllc.com Fax: 4807791327
1077	Suchet Patel	Meridian Clinical Research 415 Hooper Rd Endwell, NEW YORK 13760 UNITED STATES	Phone: 6077544081 Email: spatel@mcrmed.com Fax: 6077545730
1077	Suchet Patel	Meridian Clinical Research LLC 409 Hooper Rd Endwell, NEW YORK 13760 UNITED STATES	Phone: 6077544081 Email: spatel@mcrmed.com Fax: 6077545730
1079	George Raad	PMG Research of Charlotte LLC 1700 Abbey Place, Ste 201 Charlotte, NC 28209 UNITED STATES	Phone: (704)-527-6672 Email: graad@pmg- research.com Fax: 7045274622
1080	Sylvia Shoffner	PMG Research of Raleigh, LLC d/b/a PMG Research of Cary 530 New Waverly Place, Ste 200A Cary, NC 27518 UNITED STATES	Phone: (919) 342-3447 Email: sshoffner@carymedicalgroup.c om Fax: 9193423422
1081	Michael Butcher	Sterling Research Group, Ltd.	Phone: 5133814100

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		2230 Auburn Ave, Level B Cincinnati, OH 45219 UNITED STATES	Email: bbutcher@sterlingresearch.org Fax: 5133814120
1082	William Smith	Alliance for Multispecialty Research, LLC 1924 Alcoa Hwy, 4 and 5 Nw Knoxville, TENNESSEE 37920 UNITED STATES	Phone: (865) 305-9100x246 Email: william.smith@amrllc.com Fax: 8653052005
1082	William Smith	Alliance for Multispecialty Research, LLC. 801 N. Weisgarber Rd, Ste 100 Knoxville, TN 37909 UNITED STATES	Phone: (865) 305-9100x246 Email: william.smith@amrllc.com Fax: 8653052005
1083	Laurence Chu	Benchmark Research 3100 Red River St, Ste 1 Austin, TX 78705 UNITED STATES	Phone: +1(512)-478-5416 Email: laurencechu@benchmarkresearch.net Fax: 5128527101
1084	Douglas Denham	Clinical Trials of Texas, Inc. (Storage Only) 5430 Fredericksburg Rd., Ste 601 San Antonio, TEXAS 78229 UNITED STATES	Phone: (210) 949-0122x120 Email: ddenham@cttexas.com Fax: 2109490181
1084	Douglas Denham	Clinical Trials of Texas, Inc.	Phone: (210) 949-0122x120

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		2nd SCA 5430 Fredericksburgs Rd, Trlr San Antonio, TEXAS 78229 UNITED STATES	Email: ddenham@cttexas.com Fax: 2109490181
1084	Douglas Denham	Clinical Trials of Texas, Inc. 5430 Fredericksburg Rd, Ste 200 San Antonio, TEXAS 78229 UNITED STATES	Phone: (210) 949-0122x120 Email: ddenham@cttexas.com Fax: 2109490181
1085	Gregory Fuller	Ventavia Research Group, LLC 300 N Rufe Snow Dr Keller, TX 76248 UNITED STATES	Phone: 817-729-5252 Email: gregoryfuller@ventaviaresearch.com Fax: 8173373224
1087	Kevin Cannon	PMG Research of Wilmington, LLC 1907 Tradd Court Wilmington, NC 28401 UNITED STATES	Phone: (910)-799-5500 Email: kevin.cannon@accellacare.com Fax:
1088	John Earl	PMG Research of Hickory, LLC 221 13th Ave Pl NW, Ste 201 Hickory, NC 28601 UNITED STATES	Phone: +1(828)-345-5060 Email: jearl@pmg-research.com Fax:
1089	Cecil Farrington	PMG Research of Salisbury, LLC	Phone: (704) 647-9913

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		410 Mocksville Ave Salisbury, NC 28144 UNITED STATES	Email: cmfarrington@pmg- research.com Fax: 7046479575
1090	Lisa Cohen (Wayne Harper)	M3 Wake Research, Inc. 3100 Duraleigh Rd, Ste 304 Raleigh, NC 27612 UNITED STATES	Phone: (919)-781-2514 Email: lcohen@wakeresearch.com Fax: (Phone: (919)-781-2514 Email: wharper@wakeresearch.com Fax: 9194206067)
1091	Samir Arora	Aventiv Research Inc (Facility and Drug Shipment Address) 99 N. Brice Rd, Ste 260 Columbus, OHIO 43213 UNITED STATES	Phone: (614)-501-6164 Email: sarora@aventivresearch.com Fax: 6145016165
1091	Samir Arora	Aventiv Research Inc. 99 N. Brice Rd, Ste 210 Columbus, OHIO 43213 UNITED STATES	Phone: (614)-501-6164 Email: sarora@aventivresearch.com Fax: 6145016165
1092	Rajesh Davit	Sterling Research Group, Ltd. 375 Glensprings Dr, 2nd Fl	Phone: 5136718080 Email: rdavit@sterlingresearch.org

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Cincinnati, OH 45246 UNITED STATES	Fax: 5136718090
1093	David Ensz	Meridian Clinical Research, LLC 4802 Sunnybrook Dr Sioux City, IOWA 51106 UNITED STATES	Phone: (605)-232-9000 Email: ensz@mcrmed.com Fax: 7122548825
1094	Murtaza Mussaji	LinQ Research, LLC 11021 Shadow Creek Pkwy, Ste 102 Pearland, TEXAS 77584 UNITED STATES	Phone: 281-916-4220 ext. 102 Email: murtaza@linqresearchllc.com Fax: 2819164221
1095	Paul Pickrell	Tekton Research, Inc. 4534 W Gate Blvd., Ste 110 Austin, TEXAS 78745 UNITED STATES	Phone: 5123885717 Email: ppickrell@tektonresearch.com Fax:
1096	Van Tran	Dr. Van Tran Family Practice 1919 N Loop W, Ste 218 Houston, TEXAS 77008 UNITED STATES	Phone: 832-831-5349 Email: vantran@ventaviaresearch.com Fax:
1096	Van Tran	Hany H. Ahmed, MD 1919 N Loop W, 140	Phone: 832-831-5349 Email: vantran@ventaviaresearch.com

090177e1968ea843\Final\Final On: 18-Mar-2021 14:01 (GMT)

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Houston, TX 77008 UNITED STATES	Fax:
1096	Van Tran	Ventavia Research Group, LLC 1919 N Loop W, Ste 250 Houston, TX 77008 UNITED STATES	Phone: 832-831-5349 Email: vantran@ventaviaresearch.com Fax:
1097	Tom Christensen	Main Street Physician's Care 3600 Sea Mountain Hwy, Ste C Little River, SOUTH CAROLINA 29566 UNITED STATES	Phone: 8433994848 Email: (b) (6)
1098	Salma Saiger	SMS Clinical Research, LLC 1210 N Galloway Ave Mesquite, TX 75149 UNITED STATES	Phone: (972)-216-5152 Email: ssaiger@smsclinicalresearch.com m Fax: 9727599053
1101	Thomas Wolf	Methodist Physicians Clinic / CCT Research 350 W 23rd St Fremont, NE 68025 UNITED STATES	Phone: 402-704-7950 Email: thomaswolf@cctresearch.com Fax: 4027047951
1107	Harry Studdard	Alliance for Multispecialty Research, LLC 100 Memorial Hospital Dr, Annex Bldg, Ste-3B	Phone: (251) 414-1984 Email: harry.studdard@amrllc.com

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Mobile, AL 36608 UNITED STATES	Fax:
1109	Bruce Rankin	DeLand Clinical Research Unit 860 Peachwood Dr DeLand, FLORIDA 32720 UNITED STATES	Phone: (386)-785-2400 Email: brankin@accelclinical.com Fax: 3867400074
1110	Jeffrey Rosen	Alliance for Multispecialty Research, LLC-Miami 370 Minorca Ave, Miami-Dade County, Coral Gables Section Coral Gables, FLORIDA 33134 UNITED STATES	Phone: (305) 445-5637 Email: jeffrey.rosen@amrllc.com Fax: 3054455815
1110	Jeffrey Rosen	Clinical Research of South Florida 370 Minorca Ave, 2nd Fl Coral Gables, FL 33134 UNITED STATES	Phone: (305) 445-5637 Email: jeffrey.rosen@amrllc.com Fax: 3054455815
1111	Michael Stephens	Fleming Island Center for Clinical Research 1679 Eagle Harbor Pkwy, Ste D Fleming Island, FL 32003 UNITED STATES	Phone: 19046210390 Email: mstephens@encoredocs.com Fax: 9046210395
1112	Nathan Segall	Clinical Research Atlanta	Phone: (770)-507-6867 Email:

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		175 Country Club Dr, Bldg 100, Ste A Stockbridge, GA 30281 UNITED STATES	nsegall@clinicalresearchatlanta.com Fax: 7705071539
1114	Richard Glover	Alliance for Multispecialty Research, LLC 700 Medical Center Dr, Ste 110 Newton, KANSAS 67114 UNITED STATES	Phone: 13168047301 Email: richard.glover@amrllc.com Fax:
1116	Paul Matherne	MedPharmics, LLC 15190 Community Rd, Ste 300 Gulfport, MISSISSIPPI 39503 UNITED STATES	Phone: (228)-206-1283 Email: paulmatherne@medpharmics.com Fax: 2282060460
1116	Paul Matherne	MedPharmics, Limited Liability Company 15190 Community Rd., Ste 350 Gulfport, MISSISSIPPI 39503 UNITED STATES	Phone: (228)-206-1283 Email: paulmatherne@medpharmics.com Fax: 2282060460
1117	Larkin Wadsworth	Sundance Clinical Research, LLC 711 Old Ballas Rd, Ste 105 St. Louis, MO 63141 UNITED STATES	Phone: (314) 567-3377 Email: ty.wadsworth@sbcglobal.net Fax: 3145673390
1118	Frank Eder	Meridian Clinical Research, LLC	Phone: (607) 771-1064 ext 41351

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		1290 Uppr Frnt St Binghamton, NEW YORK 13901 UNITED STATES	Email: feder@mcrmed.com Fax: 6077714656
1120	Paul Bradley	Meridian Clinical Research, LLC 340 Eisenhower Dr, Ste 1200 Savannah, GA 31406 UNITED STATES	Phone: (912)-443-4253 Email: pbradley@mcrmed.com Fax: 8887681400
1121	Daniel Brune	Optimal Research, LLC 4911 N. Executive Dr, 2nd Fl Peoria, ILLINOIS 61614 UNITED STATES	Phone: (309) 672-1910 Email: dbrunemd@optimalsites.net Fax:
1122	Curtis Donskey	VA Northeast Ohio Healthcare System 10701 E Blvd. Cleveland, OHIO 44106 UNITED STATES	Phone: 21679138004788 Email: curtis.donskey@va.gov Fax:
1123	Brandon Essink	Meridian Clinical Research 3319 N 107th St. Omaha, NEBRASKA 68134 UNITED STATES	Phone: 4029336500 Email: bessink@mcrmed.com Fax: 4029336501
1124	David Fried	Omega Medical Research	Phone: 4017399350 Email:

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		400 Bald Hill Rd Warwick, RHODE ISLAND 02886 UNITED STATES	dr.fried@omegamedicalresearch.com Fax: 4017399351
1125	Charles Harper	Meridian Clinical Research, LLC 1410 N 13th St, Ste 5 Norfolk, NE 68701 UNITED STATES	Phone: (402)-371-0797 Email: charper@mcrmed.com Fax: 8885888068
1126	Nicola Klein	Kaiser Permanente Sacramento 1650 Response Rd Sacramento, CA 95815 UNITED STATES	Phone: (510)-267-7538 Email: nicola.klein@kp.org Fax: 5102677524
1126	Nicola Klein	Kaiser Permanente Santa Clara 710 Lawrence Expy Santa Clara, CALIFORNIA 95051 UNITED STATES	Phone: (510)-267-7538 Email: nicola.klein@kp.org Fax: 5102677524
1127	Tracy Klein	Alliance for Multispecialty Research, LLC 1709 S Rock Rd Wichita, KS 67207 UNITED STATES	Phone: 316-689-6683 Email: tracy.klein@amrllc.com Fax:
1128	Mark Koch	Ventavia Research Group, LLC	Phone: 817-348-0228 Email:

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		1307 8th Ave, Ste 202 Fort Worth, TX 76104 UNITED STATES	markkoch@ventaviaresearch.com Fax: 8173941901
1128	Mark Koch	Ventavia Research Group, LLC 1307 8th Ave, Ste M1 Fort Worth, TX 76104 UNITED STATES	Phone: 817-348-0228 Email: markkoch@ventaviaresearch.com Fax: 8173941901
1129	Michael Koren	Jacksonville Center for Clinical Research 4085 University Blvd S, Ste 1 Jacksonville, FLORIDA 32216 UNITED STATES	Phone: 904-730-0101 Email: mkoren@encoredocs.com Fax: 9047300121
1130	Stephen Fortmann	Kaiser Permanente Northwest-Center for Health Research 3800 N Interstate Ave Portland, OR 97227 UNITED STATES	Phone: 503 335 2459 Email: stephen.p.fortmann@kpchr.org Fax: 5033356645
1131	William Randall	PriMED Clinical Research 948 Patterson Rd Dayton, OHIO 45419 UNITED STATES	Phone: +1(937)-534-4201 Email: (b) (6) Fax:
1133	Howard Schwartz	Research Centers of America	Phone: 954-990-7649

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		7261 Sheridan St, Suites 210, 215, 310 Hollywood, FLORIDA 33024 UNITED STATES	Email: howard.schwartz@rcatrials.com Fax: 7542005662
1134	Jonathan Wilson	PMG Research of Winston-Salem, LLC 1901 S. Hawthorne Rd, Ste 306 Winston-Salem, NC 27103 UNITED STATES	Phone: 13367688062 Email: jwilson@pmg- research.com Fax: 3367602957
1135	Peter Winkle	Anaheim Clinical Trials, LLC 1085 N. Harbor Blvd. Anaheim, CA 92801 UNITED STATES	Phone: 7147747777 Email: pwinkle@act-trials.com Fax: 7147780667
1135	Peter Winkle	Anaheim Clinical Trials, LLC 2441 W. La Palma Ave, Ste 140 Anaheim, CALIFORNIA 92801 UNITED STATES	Phone: 7147747777 Email: pwinkle@act-trials.com Fax: 7147780667
1136	Michael Levin	Wake Research-Clinical Research Center of Nevada, LLC 1022 E Sahara Ave Las Vegas, NEVADA 89104 UNITED STATES	Phone: (702) 893-8968 Email: mlevin@crcnnv.com Fax: 7024582478

090177e1968ea843\Final\Final On: 18-Mar-2021 14:01 (GMT)

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
1139	Emmanuel Walter	Accessioning Unit and Repository 2 Genome Court Durham, NORTH CAROLINA 27710 UNITED STATES	Phone: 9196205346 Email: chip.walter@duke.edu Fax: 9196131550
1139	Emmanuel Walter	Clinical Research Pickett Road 3024 Pickett Rd, Durham County Durham, NORTH CAROLINA 27705 UNITED STATES	Phone: 9196205346 Email: chip.walter@duke.edu Fax: 9196131550
1139	Emmanuel Walter	Duke University Medicine Circle- Duke Early Phase Clinical Research Unit 40 Duke Medicine Circle Durham, NC 27710 UNITED STATES	Phone: 9196205346 Email: chip.walter@duke.edu Fax: 9196131550
1139	Emmanuel Walter	Duke Vaccine and Trials Unit 2608 Erwin Rd, Ste 210 Durham, NORTH CAROLINA 27705 UNITED STATES	Phone: 9196205346 Email: chip.walter@duke.edu Fax: 9196131550
1140	Stephen Thomas	SUNY Upstate Medical University Global Health Research Unit 4900 Broad Rd, Physician Ofc Bldg N, Ste 4U Syracuse, NEW YORK 13215 UNITED STATES	Phone: 3154645815 Email: thomstep@upstate.edu Fax: 3154641531

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
1140	Stephen Thomas	SUNY Upstate Medical University Institute for Human Performance 505 Irving Ave, Clinical Research Unit Syracuse, NEW YORK 13210 UNITED STATES	Phone: 3154645815 Email: thomstep@upstate.edu Fax: 3154641531
1141	Patricia Winokur	University of Iowa Hospitals & Clinics 200 Hawkins Dr Iowa City, IA 52242 UNITED STATES	Phone: (319) 356-3909 Email: patricia- winokur@uiowa.edu Fax: 3193563245
1141	Patricia Winokur	University of Iowa Hospitals & Clinics Investigational Drug Services 200 Hawkins Dr, 01284 PFP Iowa City, IOWA 42242 UNITED STATES	Phone: (319) 356-3909 Email: patricia- winokur@uiowa.edu Fax: 3193563245
1142	Richard Rupp	University of Texas Medical Branch SIVS Clinical Trials Program, Primary Care Pavilion, 400 Harborside Dr., Ste 126 Galveston, TEXAS 77555 UNITED STATES	Phone: (409) 772-5278 Email: rrupp@utmb.edu Fax: 4097725275
1145	Kawsar Talaat	Center for Immunization Research Inpatient Unit Johns Hopkins Bayview Medical Center (JHBMC) 301 Mason Lord Dr, 4300	Phone: 4105029627 Email: ktalaat@jhu.edu Fax: 4105026898

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
1146	Robert Falcone	Baltimore, MD 21224 UNITED STATES Amici Clinical Research 34 E Somerset St Raritan, NJ 08869 UNITED STATES	Phone: (732)-369-9402 Email: robert.falcone@amicicr.com Fax: 7325273204
1147	Julia Garcia-Diaz	Ochsner Clinic Foundation 1514 Jefferson Hwy New Orleans, LA 70121 UNITED STATES	Phone: (504) 842-7617 Email: jgarcia- diaz@ochsner.org Fax: 5047038870
1149	Steven Reynolds	Collaborative Neuroscience Research, LLC 2600 Redondo Ave, Ste 415 Long Beach, CA 90806 UNITED STATES	Phone: 8667874257 Email: stevenreynolds@cnstrial.com Fax:
1149	Steven Reynolds	Collaborative Neuroscience Research, LLC. - Investigator Site File Location 12772 Valley View St, Ste 3 Garden Grove, CA 92845 UNITED STATES	Phone: 8667874257 Email: stevenreynolds@cnstrial.com Fax:
1149	Steven Reynolds	Collaborative Neuroscience Research, LLC. - Study Visits & IP Shipping/Storage	Phone: 8667874257 Email:

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		2600 Redondo Ave, Ste 500 Long Beach, CA 90806 UNITED STATES	stevenreynolds@cnstrial.com Fax:
1150	Shelly Senders	Senders Pediatrics 2054 S Green Rd South Euclid, OH 44121 UNITED STATES	Phone: 12162919210 Email: ssenders@senderspediatrics.co m Fax: 2162918688
1152	Donald Brandon	California Research Foundation 4180 Ruffin Rd, Ste 255 San Diego, CALIFORNIA 92123-1881 UNITED STATES	Phone: 619-255-2980 Email: dbrandon@crftrials.com Fax:
1156	Hector Rodriguez	Acevedo Clinical Research Associates 2400 Nw 54th St Miami, FL 33142 UNITED STATES	Phone: (305) 649-8871 Email: hrodriguez.md@acevedoclinica lresearch.com Fax: 3056750516
1157	Jamshid Saleh	Paradigm Clinical Research Center 3652 Eureka Way Redding, CA 96001 UNITED STATES	Phone: +15302477049 Email: jsaleh@paradigm- research.com Fax: 5302477048
1161	Darrell Herrington	Benchmark Research.	Phone: 3257161355

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		3605 Executive Dr San Angelo, TEXAS 76904 UNITED STATES	Email: darrellherrington@benchmarkre search.net Fax: 3252243318
1162	Robert Riesenber	Atlanta Center for Medical Research 501 Fairburn Rd SW Atlanta, GEORGIA 30331 UNITED STATES	Phone: (404)-881-5800 Email: rriesenberg@acmr.org Fax:
1163	George Bauer	Benchmark Research 4517 Veterans Memorial Blvd Metairie, LOUISIANA 70006 UNITED STATES	Phone: 504-888-9493 Email: georgebauer@benchmarkresear ch.net Fax: 5044546868
1166	Mary Beth Manning	Rapid Medical Research, Inc. 3619 Park E Dr, Ste 300 Cleveland, OH 44122 UNITED STATES	Phone: 216-682-0320 Email: mbmanning@velocityclinical.c om Fax: 2166820326
1167	Emily Morawski	Holston Medical Group 105 W Stone Dr, 3rd Fl, Ste 3B Kingsport, TN 37660 UNITED STATES	Phone: 423-392-5883 Email: emily.morawski@myhmg.com Fax:
1168	Steven Cox	Lynn Institute of Norman	Phone: 405-701-2466

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		630 24th Ave Sw Norman, OKLAHOMA 73069 UNITED STATES	Email: scox@lhsi.net Fax: 4057012838
1169	Joseph Yozviak	Lehigh Valley Health Network/Network Office of Research and Innovation 17th & Chew Streets Allentown, PA 18102 UNITED STATES	Phone: (610) 402-9543 Email: joseph.yozviak@lvhn.org Fax: 6109692762
1170	Mezgebe Berhe	North Texas Infectious Diseases Consultants, P.A. 3409 Worth St, Ste 710, 725, 740 Dallas, TEXAS 75246 UNITED STATES	Phone: (214)823-2533 Email: mezgebe.berhe@ntidc.org Fax:
1171	Earl Martin	DM Clinical Research 13406 Medical Complex Dr, Ste 53 Tomball, TX 77375 UNITED STATES	Phone: (281)-517-0550 Email: drearlfmartin@dmclinicalresear ch.com Fax: 2819468363
1171	Earl Martin	Martin Diagnostic Clinic 710 Lawrence St Tomball, TX 77375 UNITED STATES	Phone: (281)-517-0550 Email: drearlfmartin@dmclinicalresear ch.com Fax: 2819468363

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
1174	Donald Poretz	Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID) 3289 Woodburn Rd, Ste 250 Annandale, VA 22003 UNITED STATES	Phone: 7035604821 Email: (b) (6) Fax: 7036418654
1174	Donald Poretz	Infectious Diseases Physicians, LLC 3289 Woodburn Rd, Ste 200 Annandale, VA 22003 UNITED STATES	Phone: 7035604821 Email: (b) (6) Fax: 7036418654
1177	David Fitz-Patrick	East-West Medical Research Institute 1585 Kapiolani Blvd, Ste 1500 Honolulu, HI 96814 UNITED STATES	Phone: (808)-531-6886 Email: dfitz@eastwestresearch.com Fax: 8084404425
1178	Stephan Sharp	Clinical Research Associates, Inc. 1500 Church St, Ste 100 Nashville, TN 37203 UNITED STATES	Phone: 6153290197 Email: ssharp@cranashville.com Fax:
1179	Steven Katzman	Michigan Center for Medical Research 30160 Orchard Lake Rd Farmington Hills, MI 48334 UNITED STATES	Phone: (248) 747-4383 Email: drkatzman@michmer.com Fax: 2484340179

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
1185	Marylyn Addo	Universitätsklinikum Hamburg-Eppendorf Bernhard Nocht Centre for Clinical Trials - Bernhard-Nocht-Institut für Tropenmedizin Bernhard-Nocht-Str. 74 Hamburg 20359 GERMANY	Phone: +49 (40) 7410-51102 Email: m.addo@uke.de Fax:
1194	Andreas Eich	IKF Pneumologie GmbH & Co KG Institut für klinische Forschung Schaumainkai 101-103 Frankfurt am Main 60596 GERMANY	Phone: +49 (0) 69-69 59 72 580 Email: eich@ikf- pneumologie.de Fax:
1195	Axel Schaefer	Medizentrum Essen Borbeck Huelsmannstrasse 6 Essen 45355 GERMANY	Phone: +492018664428 Email: axel.schaefer@mzeb.de Fax: 00492018664444
1197	Matthias Luttermann	Studienzentrum Brinkum Dr. Lars Pohlmeier und Torsten Drescher Melcherstaette 7 Stuhr 28816 GERMANY	Phone: +49 1739105193 Email: m.luttermann@gmx.de Fax:
1202	Armin Schultz	CRS Clinical Research Services Mannheim GmbH Grenadierstr. 1	Phone: +49 621 15045-234 Email: armin.schultz@crs- group.de

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Mannheim 68167 GERMANY	Fax: 4962115045150
1203	Sybille Baumann	CRS Clinical Research Services Berlin GmbH Sellerstr. 31 Berlin 13353 GERMANY	Phone: +49 30 859949 101 Email: sybille.baumann@crs- group.de Fax: 49062115045150
1204	Judith Aberg	Icahn School of Medicine at Mount Sinai 17 E 102nd st, 8th fl New York, NY 10029 UNITED STATES	Phone: 212-241-6741 Email: judith.aberg@mssm.edu Fax: 2122638264
1204	Judith Aberg	Icahn School of Medicine at Mount Sinai - Investigational Drug Service 1450 Madison Ave, Annenberg B2, Rm 204 New York, NY 10029 UNITED STATES	Phone: 212-241-6741 Email: judith.aberg@mssm.edu Fax: 2122638264
1205	Serhat Unal	Hacettepe Universitesi Tip Fakultesi Enfeksiyon Hastaliklari ve Klinik Mikrobiyoloji Anabilim Dali Sihhiye Ankara 06230 TURKEY	Phone: +905324883757 Email: sunal@hacettepe.edu.tr Fax: 903123104179
1207	Ismail Balik	Ankara Universitesi Tip Fakultesi, Ibnu Sina	Phone: +90532-135-2233

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Hastanesi Enfeksiyon Hastaliklari ve Klinik Mikrobiyoloji Anabilim Dali Sihhiye Ankara 06230 TURKEY	Email: (b) (6) Fax:
1208	Iftihar Koxsal	Acibadem Atakent Hastanesi Enfeksiyon Hastaliklari ve Klinik Mikrobiyoloji Birimi Kucukcekmece Istanbul 34303 TURKEY	Phone: +904623775861 Email: (b) (6) Fax:
1209	Sedat Altin	Istanbul Yedikule Gogus Hastaliklari ve Gogus Cerrahisi Egitim Arastirma Hastanesi Zeytinburnu Istanbul 34020 TURKEY	Phone: +905426523587 Email: (b) (6) Fax: 902126641700
1210	Ali Mert	Medipol Mega Universite Hastanesi Bagcilar Istanbul 34214 TURKEY	Phone: 905333962742 Email: alimert@medipol.edu.tr Fax:
1212	Oguz Karabay	Sakarya Universitesi Egitim ve Arastirma Hastanesi	Phone: +905422355355 Email: okarabay@sakarya.edu.tr

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Adapazari Sakarya 54100 TURKEY	Fax:
1213	Omer Tabak	Istanbul Universitesi-Cerrahpasa, Cerrahpasa Tıp Fakultesi Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı Fatih Istanbul 34098 TURKEY	Phone: +905322763788 Email: (b) (6) Fax:
1214	Serap Simsek-Yavuz	Istanbul Universitesi Istanbul Tıp Fakultesi Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı Fatih Istanbul 34093 TURKEY	Phone: +905052696412 Email: (b) (6) Fax:
1217	Sila Akhan	Kocaeli Universitesi Tıp Fakultesi Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı Umuttepe Kocaeli 41380 TURKEY	Phone: +905312028136 Email: sila.akhan@kocaeli.edu.tr Fax:
1218	Laura Hammitt	Johns Hopkins Center for American Indian Health 308 Kuper St. Whiteriver, ARIZONA 85941	Phone: 1 410 955 6931 Email: lhammitt@jhu.edu Fax:

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		UNITED STATES	
1218	Laura Hammitt	Whiteriver Indian Hospital 200 W Hospital Dr Whiteriver, ARIZONA 85941 UNITED STATES	Phone: 1 410 955 6931 Email: lhammitt@jhu.edu Fax:
1218	Laura Hammitt	Whiteriver Indian Hospital - Garrett Building 400 W. Apache Dr Whiteriver, ARIZONA 85941 UNITED STATES	Phone: 1 410 955 6931 Email: lhammitt@jhu.edu Fax:
1219	Laura Hammitt	Chinle Comprehensive Health Care Facility US Hwy 191 and Hospital Rd Chinle, ARIZONA 86503 UNITED STATES	Phone: 1 410 955 6931 Email: lhammitt@jhu.edu Fax:
1219	Laura Hammitt	Johns Hopkins Center for American Indian Health US Hwy 191 Chinle, ARIZONA 86503 UNITED STATES	Phone: 1 410 955 6931 Email: lhammitt@jhu.edu Fax:
1220	Laura Hammitt	Johns Hopkins Center for American Indian Health 3 Cottonwood St Shiprock, NEW MEXICO 87420	Phone: 1 410 955 6931 Email: lhammitt@jhu.edu Fax:

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		UNITED STATES	
1220	Laura Hammitt	Northern Navajo Medical Center US HWY 491 N Shiprock, NEW MEXICO 87420 UNITED STATES	Phone: 1 410 955 6931 Email: lhammitt@jhu.edu Fax:
1221	Laura Hammitt	Gallup Indian Medical Center 516 E Nizhoni Blvd Gallup, NEW MEXICO 87301 UNITED STATES	Phone: 1 410 955 6931 Email: lhammitt@jhu.edu Fax:
1221	Laura Hammitt	Johns Hopkins Center for American Indian Health 501 E. Nizhoni Blvd, Ste B Gallup, NEW MEXICO 87301 UNITED STATES	Phone: 1 410 955 6931 Email: lhammitt@jhu.edu Fax:
1223	Onyema Ogbuagu	Yale Center for Clinical Investigations (CSRU) 2 Church St S, Ste 114 New Haven, CT 06519 UNITED STATES	Phone: 516-281-4557, (516) 281-4557 Email: onyema.ogbuagu@yale.edu Fax: 2037857450
1223	Onyema Ogbuagu	Yale University School of Medicine 135 College St, Ste 392 New Haven, CT 06510	Phone: 516-281-4557, (516) 281-4557 Email: onyema.ogbuagu@yale.edu

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		UNITED STATES	Fax: 2037857450
1223	Onyema Ogbuagu	Yale-New Haven Hospital 55 Park St, LL-15 New Haven, CT 06511 UNITED STATES	Phone: 516-281-4557, (516) 281-4557 Email: onyema.ogbuagu@yale.edu Fax: 2037857450
1224	Larry Odekirk	Lynn Institute of Denver 1411 S. Potomac St, Ste 420 Aurora, CO 80012 UNITED STATES	Phone: 3033719432 Email: lodekirk@lhsi.net Fax: 3033719521
1226	Cristiano Zerbini	CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda (Casa Branca) Rua Moreira e Costa, 342 - Ipiranga Sao Paulo/SP 04266-010 BRAZIL	Phone: +55-11-2271-3498 Email: criszerb@uol.com.br Fax:
1229	Essack Mitha	Newtown Clinical Research Centre 104 Jeppe Street, Newtown, Suite 3, Newgate Centre Johannesburg, GAUTENG 2113 SOUTH AFRICA	Phone: +27823223402 Email: emitha@newtowncrc.co.za Fax:
1230	Leon Fouche	Limpopo Clinical Research Initiative Tamboti Medical Centre	Phone: +27 14 777 1939 Email:

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		11 Van der Bijl Street Thabazimbi, LIMPOPO 0380 SOUTH AFRICA	leon.fouche@iafrica.com Fax: 0027112528903
1231	Fernando Polack	Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich Luis María Campos 726 Piso 8 CABA 1426 ARGENTINA	Phone: 00549-11303-66950 Email: fpolack@i-trials.com Fax:
1232	Jeffrey Kingsley	IACT Health 800 Talbotton Rd Columbus, GA 31904 UNITED STATES	Phone: 706-321-0495 Email: jkingsley@iacthealth.com Fax:
1235	John Vanchiere	LSUHSC-Shreveport 1501 Kings Hwy Shreveport, LA 71103 UNITED STATES	Phone: 3186757076 Email: jvanch@lsuhsc.edu Fax: 3186756059
1235	John Vanchiere	LSUHSC-Shreveport Clinical Trials Office 1801 Fairfield Ave, Ste 203 Shreveport, LA 71101 UNITED STATES	Phone: 3186757076 Email: jvanch@lsuhsc.edu Fax: 3186756059
1241	Edson Moreira	Hospital Santo Antonio/ Associacao Obras Sociais	Phone: +5571-3176-2343

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Irma Dulce Avenida Dendezeiros do Bonfim, N° 161 Salvador, BAHIA CEP: 40415-006 BRAZIL	Email: edson.moreira@fiocruz.br Fax:
1246	Dany Musungaie	Jongaie Research Medicross Pretoria West, 1st Floor, 551 WF Nkomo Street Pretoria, GAUTENG 0183 SOUTH AFRICA	Phone: +27723824021 Email: dbmusungaie@outlook.com Fax:
1247	Haylene Nell	Tiervlei Trial Centre, Basement Level, Karl Bremer Hospital Clinical c/o Mike Pienaar Boulevard & Frans Conradie Avenue, Bellville Cape Town, WESTERN CAPE 7530 SOUTH AFRICA	Phone: +27 21 957 9400 Email: haylenenell@ttctrails.co.za Fax:
1248	Mohamed Al-Ibrahim	Pharmaron CPC, Inc. 800 W Baltimore St, 5th and 6th Fl Baltimore, MARYLAND 21201 UNITED STATES	Phone: 410-425-6888 Email: mohamed.al- ibrahim@pharmaron-us.com Fax: 4107068963
1251	Hayes Williams	Birmingham Clinical Research Unit 2017 Canyon Rd, Ste 41	Phone: +1(205)-757-8212 Email: hwilliams@accelclinical.com

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		Birmingham, ALABAMA 35216 UNITED STATES	Fax:
1252	Stephen Grubb	Main Street Physician's Care 3612 Mitchell St Loris, SOUTH CAROLINA 29569 UNITED STATES	Phone: 843-756-2122 Email: (b) (6) Fax: 8437562121
1254	Robert Heller	Bayview Research Group 12626 Riverside Dr, Ste 404 Valley Village, CALIFORNIA 91607 UNITED STATES	Phone: 800-831-8308 Email: rheller@bayviewresearch.com Fax: 8008318308
1258	Martin Schear	Dayton Clinical Research 1100 Salem Ave Dayton, OH 45406 UNITED STATES	Phone: 9372764311 Email: (b) (6) Fax: 9372763289
1260	Robert Finberg	UMass Memorial Medical Center - University Campus 55 Lake Ave N Worcester, MASSACHUSETTS 01655 UNITED STATES	Phone: 508-856-6970 Email: robert.finberg@umassmed.edu Fax: 5088566176
1261	Carla Greenbaum	Benaroya Research Institute at Virginia Mason	Phone: 206.342.6991 Email:

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
		925 Seneca St Seattle, WA 98101 UNITED STATES	cjgreen@benaroyaresearch.org Fax: 2063426582
1264	Timothy Albertson	UC Davis Medical Center 2315 Stockton Blvd Sacramento, CA 95817 UNITED STATES	Phone: (916)-734-3565 Email: tealbertson@ucdavis.edu Fax: 9167340861
1265	William Towner	Kaiser Permanente Los Angeles Medical Center Edgemont Medical Offices 1526 N Edgemont St Los Angeles, CA 90027 UNITED STATES	Phone: 323-783-7855 Email: william.j.towner@kp.org Fax: 3237834671
1265	William Towner	Kaiser Permanente Los Angeles Medical Center 4867 W Sunset Blvd Los Angeles, CALIFORNIA 90027 UNITED STATES	Phone: 323-783-7855 Email: william.j.towner@kp.org Fax: 3237834671
1269	Teresa Sligh	Providence Clinical Research 6400 Laurel Canyon Blvd, Ste 300A North Hollywood, CA 91606 UNITED STATES	Phone: 208-346-8900 Email: tsligh@providenceclinical.com Fax: 2085528861
1270	Nicola Klein	Kaiser Permanente Sacramento	Phone: (510)-267-7538 Email: nicola.klein@kp.org

Site Identifier	Investigator Name (Prior Clinical Investigator(s))	Site Address at Time of Clinical Study	Site Contact Information at Time of Clinical Study
1270	Nicola Klein	1650 Response Rd Sacramento, CA 95815 UNITED STATES Kaiser Permanente Santa Clara 710 Lawrence Expy Santa Clara, CALIFORNIA 95051 UNITED STATES	Fax: 5102677524 Phone: (510)-267-7538 Email: nicola.klein@kp.org Fax: 5102677524

090177e1968ea843\Final\Final On: 18-Mar-2021 14:01 (GMT)

1. TABULAR LISTING OF CLINICAL STUDIES INCLUDED IN THE BIOLOGICS LICENSE APPLICATION

Information is provided for each of the clinical studies included in the Biologics License Application (BLA) for BNT162b2. Details provided in the table include study objectives, brief descriptions of the design of each study, dose regimens, number of subjects vaccinated, a brief description of the study population, and a description of the type of Clinical Study Report (CSR) provided in the BLA.

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Table 1. Section 5.2. Listing of All Clinical Studies

Protocol No. Phase (Country)	Sponsor	Study Design and Objective(s) ^a	Treatment Groups	No. of Subjects	Demographics (by Phase)	Study Start/Status	Study Synopsis
BNT162-01 Phase 1 (Germany)	BioNTech	<p>Primary Objective:</p> <ul style="list-style-type: none"> To describe the safety and tolerability profiles of prophylactic BNT162 vaccines in healthy adults after Dose 1 only or after both Dose 1 and Dose 2 <p>Secondary Objective:</p> <ul style="list-style-type: none"> To describe the immune response in healthy adults after Dose 1 only or after Dose 1 and Dose 2 measured by a functional antibody titer, eg, virus neutralization test (VNT) or an equivalent assay available by the time of study conduct <p>Exploratory Objectives:</p> <ul style="list-style-type: none"> To describe the immune response in healthy adults after Dose 1 only or after Dose 1 and Dose 2 measured by an 	BNT162b1 (1, 3, 10, 20, 30, 50, and 60 µg)	<p>Phase 1: 120 BNT162b1</p> <p>Phase 1: 96 BNT162b2</p>	<p>Phase 1 BNT162b1: Participants 18 – 55 years of age: Sex: Male: 44 Female: 40</p> <p>Age (years): Mean/median: 38.30/36.29 Min, max: 19.9, 55.8</p> <p>Race: White: 81 Black: 1 Asian: 2</p> <p>Participants 56 – 85 years of age: Sex: Male: 13 Female: 23</p> <p>Age (years): Mean/median: 65.71/67.21 Min, max: 56.1, 76.8</p>	Start Date: April 2020 (ongoing)	BNT162-01 Interim CSR Synopsis

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Table 1. Section 5.2. Listing of All Clinical Studies

Protocol No. Phase (Country)	Sponsor	Study Design and Objective(s) ^a	Treatment Groups	No. of Subjects	Demographics (by Phase)	Study Start/Status	Study Synopsis
		antibody binding assay, eg, enzyme-linked immunosorbent assay (ELISA) or an equivalent assay available by the time of study conduct. • To describe the cell-mediated immune (CMI) responses, eg, by enzyme-linked immunosorbent-spot (ELISpot) and intracellular cytokine staining (ICS).	BNT162b2 (1, 3, 10, 20, and 30 µg)		Race: All participants were White Phase 1 BNT162b2: Participants 18 – 55 years of age: Sex: Male: 26 Female: 34 Age (years): Mean/median: 40.26/41.50 Min, max: 19.0, 55.8 Race: All participants were White. Participants 56 – 85 years of age: Sex: Male: 18 Female: 18 Age (years): Mean/median: 65.06/65.29 Min, max: 56.8, 84.0		

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Table 1. Section 5.2. Listing of All Clinical Studies

Protocol No. Phase (Country)	Sponsor	Study Design and Objective(s) ^a	Treatment Groups	No. of Subjects	Demographics (by Phase)	Study Start/Status	Study Synopsis
					Race: All participants were White.		
C4591001 Phase 1/2/3 (United States, Argentina, Brazil, Turkey, South Africa, Germany)	BioNTech (Pfizer)	<p>Phase 1</p> <p>Primary Objective:</p> <ul style="list-style-type: none"> To describe the safety and tolerability profiles of prophylactic BNT162 vaccines in healthy adults after 1 or 2 doses^g <p>Secondary Objective:</p> <ul style="list-style-type: none"> To describe the immune responses elicited by prophylactic BNT162 vaccines in healthy adults after 1 or 2 doses^g 	<p>Phase 1:</p> <p>BNT162b1 (10, 20, 30, and 100 µg) Placebo^b</p>	<p>Phase 1: 105 randomized 4:1 (within each dose/age group)</p>	<p>Phase 1:^c 18-55 year group, 100 µg & placebo Sex: Male: 6 Female: 9</p> <p>Age (years): Mean/median: 37.1/35.0 Min, max: 19, 53 Race: White: 14 Black: 0 Asian: 1</p> <p>Phase 1:^c 18-55 year group, 10, 20, 30 µg & placebo Sex: Male: 28 Female: 17</p>	<p>Start Date: April 2020 (ongoing)</p>	<p>C4591001 Final Analysis Interim CSR Synopsis</p>

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Table 1. Section 5.2. Listing of All Clinical Studies

Protocol No. Phase (Country)	Sponsor	Study Design and Objective(s) ^a	Treatment Groups	No. of Subjects	Demographics (by Phase)	Study Start/ Status	Study Synopsis
			<p>Phase 1: BNT162b2 (10, 20, and 30 µg)</p>	<p>Phase 1: 90 randomized 4:1 (within each dose/age group)</p>	<p>Age (years): Mean/median: 36.9/35.0 Min, max: 22, 54 Race: White: 37 Black: 2 Asian: 6</p> <p>Phase 1:^c 65-85 year group 10, 20, 30 µg & placebo: Sex: Male: 13 Female: 32</p> <p>Age (years): Mean/median: 69.7/69.0 Min, max: 65, 82</p> <p>Race: White: 42 Black: 1 Asian: 2</p> <p>Phase 1:^c 18-55 year group, 100 µg & placebo</p>		

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Table 1. Section 5.2. Listing of All Clinical Studies

Protocol No. Phase (Country)	Sponsor	Study Design and Objective(s) ^a	Treatment Groups	No. of Subjects	Demographics (by Phase)	Study Start/ Status	Study Synopsis
			Placebo ^b		Sex: Male: 28 Female: 17 Age (years): Mean/median: 36.9/35.0 Min, max: 22, 54 Race: White:37 Black: 2 Asian: 6 Phase 1:^c 18-55 year group: Sex: Male: 19 Female: 26 Age (years): Mean/median: 36.7/37.0 Min, max: 19,54 Race: White: 39 Black: 3 Asian: 3 Phase 1:^c 65-85 year group:		

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Table 1. Section 5.2. Listing of All Clinical Studies

Protocol No. Phase (Country)	Sponsor	Study Design and Objective(s) ^a	Treatment Groups	No. of Subjects	Demographics (by Phase)	Study Start/Status	Study Synopsis
		<p>Phase 2/3 Primary Objectives:</p> <ul style="list-style-type: none"> • Efficacy: To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID 19 occurring from 7 days after the second dose in participants without evidence of infection before vaccination⁸ • Efficacy: To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID-19 occurring from 7 days after the second dose 	<p>Phase 2: BNT162b2 (30 µg) Placebo^b</p>	<p>Phase 2: 360 randomized 1:1</p>	<p>Sex: Male: 17 Female: 28</p> <p>Age (years): Mean/median: 69.3/68.0 Min, max: 65, 81</p> <p>Race: All participants were White.</p> <p>Phase 2^d 18-85 year group: Sex: Male: 190 Female: 170</p> <p>Age (years): Mean/median: 52.6/56.0 Min, max: 18, 85</p> <p>Race: White: 309 Black: 33 American Indian or Alaska native: 2 Asian: 9 Multiracial: 3 Not reported: 4</p>		

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Table 1. Section 5.2. Listing of All Clinical Studies

Protocol No. Phase (Country)	Sponsor	Study Design and Objective(s) ^a	Treatment Groups	No. of Subjects	Demographics (by Phase)	Study Start/Status	Study Synopsis
		<p>in participants with and without evidence of infection before vaccination^g</p> <ul style="list-style-type: none"> • Safety: To define the safety profile of prophylactic BNT162b2 in the <u>first 360 participants</u> randomized (Phase 2)^h • Safety: To define the safety profile of prophylactic BNT162b2 in <u>all participants</u> randomized in Phase 2/3^g <p>Phase 2/3 Secondary Objectives:</p> <ul style="list-style-type: none"> • Efficacy: To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID-19 occurring from 14 days after the second dose in participants without evidence of infection before vaccinationⁱ 	<p>Phase 2/3: BNT162b2 (30 µg) Placebo^b</p>	<p>Phase 2/3: 43,448 randomized 1:1 (includes 360 in Phase 2)</p>	<p>Phase 2/3^e Sex: Male: 22,125 Female: 21,323</p> <p>Age (years): Mean/median: 50.0/51.0</p> <p>Min, max: 16, 91</p> <p>Race: White: 35,696 Black: 4198 American Indian or Alaska native: 319 Asian: 1864 Native Hawaiian or other Pacific Islander: 88 Multiracial: 1050 Not reported: 233</p>		
<p>C4591001 Phase 1/2/3 (United States, Argentina, Brazil, Turkey, South Africa, Germany)</p>				<p>Phase 2/3: 44,047 randomized 1:1 (includes 360 in Phase 2)</p>	<p>Phase 2/3^f Participants ≥16 years of age: Sex: Male: 22,420 Female: 21,627</p> <p>Age (years): Mean/median:</p>		<p>Interim CSR – 6-Month Update Synopsis</p>

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Table 1. Section 5.2. Listing of All Clinical Studies

Protocol No. Phase (Country)	Sponsor	Study Design and Objective(s) ^a	Treatment Groups	No. of Subjects	Demographics (by Phase)	Study Start/Status	Study Synopsis
		<ul style="list-style-type: none"> • Efficacy: To evaluate the efficacy of prophylactic BNT162b2 against confirmed severe COVID-19 occurring from 7 days and from 14 days after the second dose in participants with and without evidence of infection before vaccinationⁱ • Efficacy: To describe the efficacy of prophylactic BNT162b2 against confirmed COVID-19 (according to the CDC-defined symptoms) occurring from 7 days and from 14 days after the second dose in participants without evidence of infection before vaccinationⁱ • Efficacy: To describe the efficacy of prophylactic 			49.7/51.0 Min, max: 16, 91 Race: White: 36,120 Black: 4216 American Indian or Alaska native: 438 Asian: 1894 Native Hawaiian or other Pacific Islander: 90 Multiracial: 1083 Not reported: 206 Racial designation: Japanese: 156		

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Table 1. Section 5.2. Listing of All Clinical Studies

Protocol No. Phase (Country)	Sponsor	Study Design and Objective(s) ^a	Treatment Groups	No. of Subjects	Demographics (by Phase)	Study Start/Status	Study Synopsis
		<p>BNT162b2 against confirmed COVID-19 (according to the CDC-defined symptoms) occurring from 7 days and from 14 days after the second dose in participants with and without evidence of infection before vaccinationⁱ</p> <p>• Exploratory Objectives: To evaluate the immune response over time to prophylactic BNT162b2 and persistence of immune response in participants with and without serological or virological evidence of SARS-CoV-2 infection before vaccination^h</p> <p>• To describe the safety, immunogenicity, and efficacy of prophylactic</p>					

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Table 1. Section 5.2. Listing of All Clinical Studies

Protocol No. Phase (Country)	Sponsor	Study Design and Objective(s) ^a	Treatment Groups	No. of Subjects	Demographics (by Phase)	Study Start/Status	Study Synopsis
		BNT162b2 in individuals with confirmed stable HIV disease ^k					
<p>a. Includes only the objectives addressed in the submission.</p> <p>b. Participants ≥16 years of age who originally received placebo and became eligible for receipt of BNT162b2 had an opportunity to receive BNT162b2 as part of the study.</p> <p>c. C4591001 safety population, cutoff date: 24 August 2020</p> <p>d. C4591001 safety population, cutoff date: 02 September 2020.</p> <p>e. C4591001 safety population, cutoff date: 14 November 2020.</p> <p>f. C4591001 safety population, cutoff date: 13 March 2021.</p> <p>g. Reported in the final analysis interim CSR with updated data reported in the interim CSR - 6-month update.</p> <p>h. Interim data are reported in the final analysis interim CSR.</p> <p>i. Prespecified complete efficacy data reported in final analysis interim CSR.</p> <p>j. Prespecified complete efficacy data reported in final analysis interim CSR with updated efficacy data (for 7 days after second dose only) reported in the interim CSR – 6-month update.</p> <p>k. Safety data only in participants with confirmed stable HIV disease are reported in the interim CSR – 6-month update.</p>							

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

Document Approval Record

Document Name:	2021 COVID-19 Vaccine BLA 5.2 Tabular Listing of All Clinical Studies
Document Title:	2021 COVID-19 Vaccine BLA 5.2 Tabular Listing of All Clinical Studies

Signed By:	Date(GMT)	Signing Capacity
Perez, John	29-Apr-2021 20:25:55	Final Approval

090177e196ea740d\Approved\Approved On: 29-Apr-2021 20:25 (GMT)

5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021

Report Prepared by:

Worldwide Safety

Pfizer

The information contained in this document is proprietary and confidential. Any disclosure, reproduction, distribution, or other dissemination of this information outside of Pfizer, its Affiliates, its Licensees, or Regulatory Agencies is strictly prohibited. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor to use it for unauthorized purposes.

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

TABLE OF CONTENTS

LIST OF TABLES3
LIST OF FIGURES3
APPENDICES3
LIST OF ABBREVIATIONS.....4
1. INTRODUCTION5
2. METHODOLOGY5
3. RESULTS6
 3.1. Safety Database6
 3.1.1. General Overview6
 3.1.2. Summary of Safety Concerns in the US Pharmacovigilance Plan9
 3.1.3. Review of Adverse Events of Special Interest (AESIs)16
 3.1.4. Medication error26
4. DISCUSSION28
5. SUMMARY AND CONCLUSION29

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

LIST OF TABLES

Table 1. General Overview: Selected Characteristics of All Cases Received During the Reporting Interval.....7

Table 2. Events Reported in $\geq 2\%$ Cases.....8

Table 3. Safety concerns9

Table 4. Important Identified Risk.....10

Table 5. Important Potential Risk11

Table 6. Description of Missing Information12

Table 7. AESIs Evaluation for BNT162b2.....16

Table 8. ME PTs by seriousness with or without harm co-association (Through 28 February 2021)27

LIST OF FIGURES

Figure 1. Total Number of 13vPnC AEs by System Organ Classes and Event Seriousness8

APPENDICES

APPENDIX 1 LIST OF ADVERSE EVENTS OF SPECIAL INTEREST30

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

LIST OF ABBREVIATIONS

Acronym	Term
AE	adverse event
AESI	adverse event of special interest
BC	Brighton Collaboration
CDC	Centers for Disease Control and Prevention
COVID-19	coronavirus disease 2019
DLP	data lock point
EUA	emergency use authorisation
HLGT	(MedDRA) High Group Level Term
HLT	(MedDRA) High Level Term
MAH	marketing authorisation holder
MedDRA	medical dictionary for regulatory activities
MHRA	Medicines and Healthcare products Regulatory Agency
PCR	Polymerase Chain Reaction
PT	(MedDRA) Preferred Term
PVP	pharmacovigilance plan
RT-PCR	Reverse Transcription-Polymerase Chain Reaction
RSI	reference safety information
TME	targeted medically event
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
SMQ	standardised MedDRA query
SOC	(MedDRA) System Organ Class
UK	United Kingdom
US	United States
VAED	vaccine-associated enhanced disease
VAERD	vaccine-associated enhanced respiratory disease
VAERS	vaccine adverse event reporting system

1. INTRODUCTION

Reference is made to the Request for Comments and Advice submitted 04 February 2021 regarding Pfizer/BioNTech's proposal for the clinical and post-authorization safety data package for the Biologics License Application (BLA) for our investigational COVID-19 Vaccine (BNT162b2). Further reference is made to the Agency's 09 March 2021 response to this request, and specifically, the following request from the Agency.

“Monthly safety reports primarily focus on events that occurred during the reporting interval and include information not relevant to a BLA submission such as line lists of adverse events by country. We are most interested in a cumulative analysis of post-authorization safety data to support your future BLA submission. Please submit an integrated analysis of your cumulative post-authorization safety data, including U.S. and foreign post-authorization experience, in your upcoming BLA submission. Please include a cumulative analysis of the Important Identified Risks, Important Potential Risks, and areas of Important Missing Information identified in your Pharmacovigilance Plan, as well as adverse events of special interest and vaccine administration errors (whether or not associated with an adverse event). Please also include distribution data and an analysis of the most common adverse events. In addition, please submit your updated Pharmacovigilance Plan with your BLA submission.”

This document provides an integrated analysis of the cumulative post-authorization safety data, including U.S. and foreign post-authorization adverse event reports received through 28 February 2021.

2. METHODOLOGY

Pfizer is responsible for the management post-authorization safety data on behalf of the MAH BioNTech according to the Pharmacovigilance Agreement in place. Data from BioNTech are included in the report when applicable.

Pfizer's safety database contains cases of AEs reported spontaneously to Pfizer, cases reported by the health authorities, cases published in the medical literature, cases from Pfizer-sponsored marketing programs, non-interventional studies, and cases of serious AEs reported from clinical studies regardless of causality assessment.

The limitations of post-marketing adverse drug event reporting should be considered when interpreting these data:

- Reports are submitted voluntarily, and the magnitude of underreporting is unknown. Some of the factors that may influence whether an event is reported include: length of time since marketing, market share of the drug, publicity about a drug or an AE, seriousness of the reaction, regulatory actions, awareness by health professionals and consumers of adverse drug event reporting, and litigation.
- Because many external factors influence whether or not an AE is reported, the spontaneous reporting system yields reporting proportions not incidence rates. As a result, it is generally not appropriate to make between-drug comparisons using these

proportions; the spontaneous reporting system should be used for signal detection rather than hypothesis testing.

- In some reports, clinical information (such as medical history, validation of diagnosis, time from drug use to onset of illness, dose, and use of concomitant drugs) is missing or incomplete, and follow-up information may not be available.
- An accumulation of adverse event reports (AERs) does not necessarily indicate that a particular AE was caused by the drug; rather, the event may be due to an underlying disease or some other factor(s) such as past medical history or concomitant medication.
- Among adverse event reports received into the Pfizer safety database during the cumulative period, only those having a complete workflow cycle in the safety database (meaning they progressed to Distribution or Closed workflow status) are included in the monthly SMSR. This approach prevents the inclusion of cases that are not fully processed hence not accurately reflecting final information. Due to the large numbers of spontaneous adverse event reports received for the product, the MAH has prioritised the processing of serious cases, in order to meet expedited regulatory reporting timelines and ensure these reports are available for signal detection and evaluation activity. The increased volume of reports has not impacted case processing for serious reports, and compliance metrics continue to be monitored weekly with prompt action taken as needed to maintain compliance with expedited reporting obligations. Non-serious cases are entered into the safety database no later than 4 calendar days from receipt. Entrance into the database includes the coding of all adverse events; this allow for a manual review of events being received but may not include immediate case processing to completion. Non-serious cases are processed as soon as possible and no later than 90 days from receipt. Pfizer has also taken a multiple actions to help alleviate the large increase of adverse event reports. This includes significant technology enhancements, and process and workflow solutions, as well as increasing the number of data entry and case processing colleagues. To date, Pfizer has onboarded approximately (b) (4) additional full-time employees (FTEs). More are joining each month with an expected total of more than (b) (4) additional resources by the end of June 2021.

3. RESULTS

3.1. Safety Database

3.1.1. General Overview

It is estimated that approximately (b) (4) doses of BNT162b2 were shipped worldwide from the receipt of the first temporary authorisation for emergency supply on 01 December 2020 through 28 February 2021.

Cumulatively, through 28 February 2021, there was a total of 42,086 case reports (25,379 medically confirmed and 16,707 non-medically confirmed) containing 158,893 events. Most cases (34,762) were received from United States (13,739), United Kingdom (13,404) Italy (2,578), Germany (1913), France (1506), Portugal (866) and Spain (756); the remaining 7,324 were distributed among 56 other countries.

Table 1 below presents the main characteristics of the overall cases.

Table 1. General Overview: Selected Characteristics of All Cases Received During the Reporting Interval

	Characteristics	Relevant cases (N=42086)
Gender:	Female	29914
	Male	9182
	No Data	2990
Age range (years): 0.01 -107 years Mean = 50.9 years n = 34952	≤ 17	175 ^a
	18-30	4953
	31-50	13886
	51-64	7884
	65-74	3098
	≥ 75	5214
	Unknown	6876
Case outcome:	Recovered/Recovering	19582
	Recovered with sequelae	520
	Not recovered at the time of report	11361
	Fatal	1223
	Unknown	9400

a. in 46 cases reported age was <16-year-old and in 34 cases <12-year-old.

As shown in [Figure 1](#), the System Organ Classes (SOCs) that contained the greatest number ($\geq 2\%$) of events, in the overall dataset, were General disorders and administration site conditions (51,335 AEs), Nervous system disorders (25,957), Musculoskeletal and connective tissue disorders (17,283), Gastrointestinal disorders (14,096), Skin and subcutaneous tissue disorders (8,476), Respiratory, thoracic and mediastinal disorders (8,848), Infections and infestations (4,610), Injury, poisoning and procedural complications (5,590), and Investigations (3,693).

Figure 1. Total Number of BNT162b2 AEs by System Organ Classes and Event Seriousness




Table 2 shows the most commonly ($\geq 2\%$) reported MedDRA (v. 23.1) PTs in the overall dataset (through 28 February 2021),

Table 2. Events Reported in $\geq 2\%$ Cases

MedDRA SOC	MedDRA PT	Cumulatively Through 28 February 2021 AEs (AERP%) N = 42086
Blood and lymphatic system disorders		
	Lymphadenopathy	1972 (4.7%)
Cardiac disorders		
	Tachycardia	1098 (2.6%)
Gastrointestinal disorders		
	Nausea	5182 (12.3%)
	Diarrhoea	1880 (4.5%)
	Vomiting	1698 (4.0%)
General disorders and administration site conditions		
	Pyrexia	7666 (18.2%)
	Fatigue	7338 (17.4%)
	Chills	5514 (13.1%)
	Vaccination site pain	5181 (12.3%)

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

Table 2. Events Reported in $\geq 2\%$ Cases

		Cumulatively Through 28 February 2021
MedDRA SOC	MedDRA PT	AEs (AERP%) N = 42086
	Pain	3691 (8.8%)
	Malaise	2897 (6.9%)
	Asthenia	2285 (5.4%)
	Drug ineffective	2201 (5.2%)
	Vaccination site erythema	930 (2.2%)
	Vaccination site swelling	913 (2.2%)
	Influenza like illness	835 (2%)
Infections and infestations		
	COVID-19	1927 (4.6%)
Injury, poisoning and procedural complications		
	Off label use	880 (2.1%)
	Product use issue	828 (2.0%)
Musculoskeletal and connective tissue disorders		
	Myalgia	4915 (11.7%)
	Pain in extremity	3959 (9.4%)
	Arthralgia	3525 (8.4%)
Nervous system disorders		
	Headache	10131 (24.1%)
	Dizziness	3720 (8.8%)
	Paraesthesia	1500 (3.6%)
	Hypoaesthesia	999 (2.4%)
Respiratory, thoracic and mediastinal disorders		
	Dyspnoea	2057 (4.9%)
	Cough	1146 (2.7%)
	Oropharyngeal pain	948 (2.3%)
Skin and subcutaneous tissue disorders		
	Pruritus	1447 (3.4%)
	Rash	1404 (3.3%)
	Erythema	1044 (2.5%)
	Hyperhidrosis	900 (2.1%)
	Urticaria	862 (2.1%)
Total number of events		93473

3.1.2. Summary of Safety Concerns in the US Pharmacovigilance Plan**Table 3. Safety concerns**

Important identified risks	Anaphylaxis
Important potential risks	Vaccine-Associated Enhanced Disease (VAED), Including Vaccine-associated Enhanced Respiratory Disease (VAERD)
Missing information	Use in Pregnancy and lactation Use in Paediatric Individuals <12 Years of Age Vaccine Effectiveness

Table 4. Important Identified Risk

Topic	Description														
Important Identified Risk	Post Authorization Cases Evaluation (cumulative to 28 Feb 2021) Total Number of Cases in the Reporting Period (N=42086)														
Anaphylaxis	<p>Since the first temporary authorization for emergency supply under Regulation 174 in the UK (01 December 2020) and through 28 February 2021, 1833 potentially relevant cases were retrieved from the Anaphylactic reaction SMQ (Narrow and Broad) search strategy, applying the MedDRA algorithm. These cases were individually reviewed and assessed according to Brighton Collaboration (BC) definition and level of diagnostic certainty as shown in the Table below:</p> <table border="1" data-bbox="423 569 1276 768"> <thead> <tr> <th>Brighton Collaboration Level</th> <th>Number of cases</th> </tr> </thead> <tbody> <tr> <td>BC 1</td> <td>290</td> </tr> <tr> <td>BC 2</td> <td>311</td> </tr> <tr> <td>BC 3</td> <td>10</td> </tr> <tr> <td>BC 4</td> <td>391</td> </tr> <tr> <td>BC 5</td> <td>831</td> </tr> <tr> <td><i>Total</i></td> <td>1833</td> </tr> </tbody> </table> <p>Level 1 indicates a case with the highest level of diagnostic certainty of anaphylaxis, whereas the diagnostic certainty is lowest for Level 3. Level 4 is defined as “reported event of anaphylaxis with insufficient evidence to meet the case definition” and Level 5 as not a case of anaphylaxis.</p> <p>There were 1002 cases (54.0% of the potentially relevant cases retrieved), 2958 potentially relevant events, from the Anaphylactic reaction SMQ (Broad and Narrow) search strategy, meeting BC Level 1 to 4:</p> <p>Country of incidence: UK (261), US (184), Mexico (99), Italy (82), Germany (67), Spain (38), France (36), Portugal (22), Denmark (20), Finland, Greece (19 each), Sweden (17), Czech Republic , Netherlands (16 each), Belgium, Ireland (13 each), Poland (12), Austria (11); the remaining 57 cases originated from 15 different countries.</p> <p>Relevant event seriousness: Serious (2341), Non-Serious (617);</p> <p>Gender: Females (876), Males (106), Unknown (20);</p> <p>Age (n=961) ranged from 16 to 98 years (mean = 54.8 years, median = 42.5 years);</p> <p>Relevant even outcome^a: fatal (9)^b, resolved/resolving (1922), not resolved (229), resolved with sequelae (48), unknown (754);</p> <p>Most frequently reported relevant PTs (≥2%), from the Anaphylactic reaction SMQ (Broad and Narrow) search strategy: Anaphylactic reaction (435), Dyspnoea (356), Rash (190), Pruritus (175), Erythema (159), Urticaria (133), Cough (115), Respiratory distress, Throat tightness (97 each), Swollen tongue (93), Anaphylactic shock (80), Hypotension (72), Chest discomfort (71), Swelling face (70), Pharyngeal swelling (68), and Lip swelling (64).</p> <p>Conclusion: Evaluation of BC cases Level 1 - 4 did not reveal any significant new safety information. Anaphylaxis is appropriately described in the product labeling as are non-anaphylactic hypersensitivity events. Surveillance will continue.</p>	Brighton Collaboration Level	Number of cases	BC 1	290	BC 2	311	BC 3	10	BC 4	391	BC 5	831	<i>Total</i>	1833
Brighton Collaboration Level	Number of cases														
BC 1	290														
BC 2	311														
BC 3	10														
BC 4	391														
BC 5	831														
<i>Total</i>	1833														

a Different clinical outcome may be reported for an event that occurred more than once to the same individual.

b There were 4 individuals in the anaphylaxis evaluation who died on the same day they were vaccinated. Although these patients experienced adverse events (9) that are potential symptoms of anaphylaxis, they all had serious underlying medical conditions, and one individual appeared to also have COVID-19 pneumonia, that likely contributed to their deaths

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

Table 5. Important Potential Risk

Topic	Description
Important Potential Risk	Post Authorization Cases Evaluation (cumulative to 28 Feb 2021) Total Number of Cases in the Reporting Period (N=42086)
Vaccine-Associated Enhanced Disease (VAED), including Vaccine-Associated Respiratory Disease (VAERD)	<p>No post-authorized AE reports have been identified as cases of VAED/VAERD, therefore, there is no observed data at this time. An expected rate of VAED is difficult to establish so a meaningful observed/expected analysis cannot be conducted at this point based on available data. The feasibility of conducting such an analysis will be re-evaluated on an ongoing basis as data on the virus grows and the vaccine safety data continues to accrue.</p> <p>The search criteria utilised to identify potential cases of VAED for this report includes PTs indicating a lack of effect of the vaccine and PTs potentially indicative of severe or atypical COVID-19^a.</p> <p>Since the first temporary authorization for emergency supply under Regulation 174 in the UK (01 December 2020) and through 28 February 2021, 138 cases [0.33% of the total PM dataset], reporting 317 potentially relevant events were retrieved:</p> <p>Country of incidence: UK (71), US (25), Germany (14), France, Italy, Mexico, Spain, (4 each), Denmark (3); the remaining 9 cases originated from 9 different countries; Cases Seriousness: 138; Seriousness criteria for the total 138 cases: Medically significant (71, of which 8 also serious for disability), Hospitalization required (non-fatal/non-life threatening) (16, of which 1 also serious for disability), Life threatening (13, of which 7 were also serious for hospitalization), Death (38). Gender: Females (73), Males (57), Unknown (8); Age (n=132) ranged from 21 to 100 years (mean = 57.2 years, median = 59.5); Case outcome: fatal (38), resolved/resolving (26), not resolved (65), resolved with sequelae (1), unknown (8); Of the 317 relevant events, the most frequently reported PTs (≥2%) were: Drug ineffective (135), Dyspnoea (53), Diarrhoea (30), COVID-19 pneumonia (23), Vomiting (20), Respiratory failure (8), and Seizure (7).</p> <p>Conclusion: VAED may present as severe or unusual clinical manifestations of COVID-19. Overall, there were 37 subjects with suspected COVID-19 and 101 subjects with confirmed COVID-19 following one or both doses of the vaccine; 75 of the 101 cases were severe, resulting in hospitalisation, disability, life-threatening consequences or death. None of the 75 cases could be definitively considered as VAED/VAERD.</p> <p>In this review of subjects with COVID-19 following vaccination, based on the current evidence, VAED/VAERD remains a theoretical risk for the vaccine. Surveillance will continue.</p>

- a. Search criteria: Standard Decreased Therapeutic Response Search AND PTs Dyspnoea; Tachypnoea; Hypoxia; COVID 19 pneumonia; Respiratory Failure; Acute Respiratory Distress Syndrome; Cardiac Failure; Cardiogenic shock; Acute myocardial infarction; Arrhythmia; Myocarditis; Vomiting; Diarrhoea; Abdominal pain; Jaundice; Acute hepatic failure; Deep vein thrombosis; Pulmonary embolism; Peripheral Ischaemia; Vasculitis; Shock; Acute kidney injury; Renal failure; Altered state of consciousness; Seizure; Encephalopathy; Meningitis; Cerebrovascular accident; Thrombocytopenia; Disseminated intravascular coagulation; Chillblains; Erythema multiforme; Multiple organ dysfunction syndrome; Multisystem inflammatory syndrome in children.

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

Table 6. Description of Missing Information

Topic	Description
Missing Information	Post Authorization Cases Evaluation (cumulative to 28 Feb 2021) Total Number of Cases in the Reporting Period (N=42086)
Use in Pregnancy and lactation	<ul style="list-style-type: none"> • Number of cases: 413^a (0.98% of the total PM dataset); 84 serious and 329 non-serious; • Country of incidence: US (205), UK (64), Canada (31), Germany (30), Poland (13), Israel (11); Italy (9), Portugal (8), Mexico (6), Estonia, Hungary and Ireland, (5 each), Romania (4), Spain (3), Czech Republic and France (2 each), the remaining 10 cases were distributed among 10 other countries. <p>Pregnancy cases: 274 cases including:</p> <ul style="list-style-type: none"> • 270 mother cases and 4 foetus/baby cases representing 270 unique pregnancies (the 4 foetus/baby cases were linked to 3 mother cases; 1 mother case involved twins). • Pregnancy outcomes for the 270 pregnancies were reported as spontaneous abortion (23), outcome pending (5), premature birth with neonatal death, spontaneous abortion with intrauterine death (2 each), spontaneous abortion with neonatal death, and normal outcome (1 each). No outcome was provided for 238 pregnancies (note that 2 different outcomes were reported for each twin, and both were counted). • 146 non-serious mother cases reported exposure to vaccine in utero without the occurrence of any clinical adverse event. The exposure PTs coded to the PTs Maternal exposure during pregnancy (111), Exposure during pregnancy (29) and Maternal exposure timing unspecified (6). Trimester of exposure was reported in 21 of these cases: 1st trimester (15 cases), 2nd trimester (7), and 3rd trimester (2). • 124 mother cases, 49 non-serious and 75 serious, reported clinical events, which occurred in the vaccinated mothers. Pregnancy related events reported in these cases coded to the PTs Abortion spontaneous (25), Uterine contraction during pregnancy, Premature rupture of membranes, Abortion, Abortion missed, and Foetal death (1 each). Other clinical events which occurred in more than 5 cases coded to the PTs Headache (33), Vaccination site pain (24), Pain in extremity and Fatigue (22 each), Myalgia and Pyrexia (16 each), Chills (13) Nausea (12), Pain (11), Arthralgia (9), Lymphadenopathy and Drug ineffective (7 each), Chest pain, Dizziness and Asthenia (6 each), Malaise and COVID-19 (5 each). Trimester of exposure was reported in 22 of these cases: 1st trimester (19 cases), 2nd trimester (1 case), 3rd trimester (2 cases). • 4 serious foetus/baby cases reported the PTs Exposure during pregnancy, Foetal growth restriction, Maternal exposure during pregnancy, Premature baby (2 each), and Death neonatal (1). Trimester of exposure was reported for 2 cases (twins) as occurring during the 1st trimester. <p>Breast feeding baby cases: 133, of which:</p> <ul style="list-style-type: none"> • 116 cases reported exposure to vaccine during breastfeeding (PT Exposure via breast milk) without the occurrence of any clinical adverse events; • 17 cases, 3 serious and 14 non-serious, reported the following clinical events that occurred in the infant/child exposed to vaccine via breastfeeding: Pyrexia (5), Rash (4), Infant irritability (3), Infantile vomiting, Diarrhoea, Insomnia, and Illness (2 each), Poor feeding infant, Lethargy, Abdominal discomfort, Vomiting, Allergy to vaccine, Increased appetite, Anxiety, Crying, Poor quality sleep, Eructation, Agitation, Pain and Urticaria (1 each). <p>Breast feeding mother cases (6):</p> <ul style="list-style-type: none"> • 1 serious case reported 3 clinical events that occurred in a mother during breast feeding (PT Maternal exposure during breast feeding); these events coded to the PTs Chills, Malaise, and Pyrexia • 1 non-serious case reported with very limited information and without associated AEs.

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

Table 6. Description of Missing Information

Topic	Description
Missing Information	Post Authorization Cases Evaluation (cumulative to 28 Feb 2021) Total Number of Cases in the Reporting Period (N=42086)
	<ul style="list-style-type: none"> • In 4 cases (3 non-serious; 1 serious) Suppressed lactation occurred in a breast feeding women with the following co-reported events: Pyrexia (2), Paresis, Headache, Chills, Vomiting, Pain in extremity, Arthralgia, Breast pain, Scar pain, Nausea, Migraine, Myalgia, Fatigue and Breast milk discolouration (1 each). <p>Conclusion: There were no safety signals that emerged from the review of these cases of use in pregnancy and while breast feeding.</p>
Use in Paediatric Individuals <12 Years of Age	<p style="text-align: center;"><u>Paediatric individuals <12 years of age</u></p> <ul style="list-style-type: none"> • Number of cases: 34^d (0.1% of the total PM dataset), indicative of administration in paediatric subjects <12 years of age; • Country of incidence: UK (29), US (3), Germany and Andorra (1 each); • Cases Seriousness: Serious (24), Non-Serious (10); • Gender: Females (25), Males (7), Unknown (2); • Age (n=34) ranged from 2 months to 9 years, mean = 3.7 years, median = 4.0; • Case outcome: resolved/resolving (16), not resolved (13), and unknown (5). • Of the 132 reported events, those reported more than once were as follows: Product administered to patient of inappropriate age (27, see Medication Error), Off label use (11), Pyrexia (6), Product use issue (5), Fatigue, Headache and Nausea (4 each), Vaccination site pain (3), Abdominal pain upper, COVID-19, Facial paralysis, Lymphadenopathy, Malaise, Pruritus and Swelling (2 each). <p>Conclusion: No new significant safety information was identified based on a review of these cases compared with the non-paediatric population.</p>
Vaccine Effectiveness	<p>Company conventions for coding cases indicative of lack of efficacy:</p> <p>The coding conventions for lack of efficacy in the context of administration of the COVID-19 vaccine were revised on 15 February 2021, as shown below:</p> <ul style="list-style-type: none"> • PT “Vaccination failure” is coded when ALL of the following criteria are met: <ul style="list-style-type: none"> ○ The subject has received the series of two doses per the dosing regimen in local labeling. ○ At least 7 days have elapsed since the second dose of vaccine has been administered. ○ The subject experiences SARS-CoV-2 infection (confirmed laboratory tests). • PT “Drug ineffective” is coded when either of the following applies: <ul style="list-style-type: none"> ○ The infection is not confirmed as SARS-CoV-2 through laboratory tests (irrespective of the vaccination schedule). This includes scenarios where LOE is stated or implied, e.g., “the vaccine did not work”, “I got COVID-19”. ○ It is unknown: <ul style="list-style-type: none"> ▪ Whether the subject has received the series of two doses per the dosing regimen in local labeling; ▪ How many days have passed since the first dose (including unspecified number of days like” a few days”, “some days”, etc.); ▪ If 7 days have passed since the second dose; ○ The subject experiences a vaccine preventable illness 14 days after receiving the first dose up to and through 6 days after receipt of the second dose. <p>Note: after the immune system as had sufficient time (14 days) to respond to the vaccine, a report of COVID-19 is considered a potential lack of efficacy even if the vaccination course is not complete.</p> <p>Summary of the coding conventions for onset of vaccine preventable disease versus the vaccination date:</p>

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

Table 6. Description of Missing Information

Topic	Description		
Missing Information	Post Authorization Cases Evaluation (cumulative to 28 Feb 2021) Total Number of Cases in the Reporting Period (N=42086)		
	1st dose (day 1-13)	From day 14 post 1st dose to day 6 post 2nd dose	Day 7 post 2nd dose
	Code only the events describing the SARS-CoV-2 infection	Code “Drug ineffective”	Code “Vaccination failure”
	Scenario Not considered LOE	Scenario considered LOE as “Drug ineffective”	Scenario considered LOE as “Vaccination failure”
	<p>Lack of efficacy cases</p> <ul style="list-style-type: none"> • Number of cases: 1665^b (3.9 % of the total PM dataset) of which 1100 were medically confirmed and 565 non medically confirmed; • Number of lack of efficacy events: 1665 [PT: Drug ineffective (1646) and Vaccination failure (19)^f]. • Country of incidence: US (665), UK (405), Germany (181), France (85), Italy (58), Romania (47), Belgium (33), Israel (30), Poland (28), Spain (21), Austria (18), Portugal (17), Greece (15), Mexico (13), Denmark (8), Canada (7), Hungary, Sweden and United Arab Emirates (5 each), Czech Republic (4), Switzerland (3); the remaining 12 cases originated from 9 different countries. • COVID-19 infection was suspected in 155 cases, confirmed in 228 cases, in 1 case it was reported that the first dose was not effective (no other information). • COVID-19 infection (suspected or confirmed) outcome was reported as resolved/resolving (165), not resolved (205) or unknown (1230) at the time of the reporting; there were 65 cases where a fatal outcome was reported. <p>Drug ineffective cases (1649)</p> <ul style="list-style-type: none"> • Drug ineffective event seriousness: serious (1625), non-serious (21)^e; • Lack of efficacy term was reported: <ul style="list-style-type: none"> ○ after the 1st dose in 788 cases ○ after the 2nd dose in 139 cases ○ in 722 cases it was unknown after which dose the lack of efficacy occurred. • Latency of lack of efficacy term reported after the first dose was known for 176 cases: <ul style="list-style-type: none"> ○ Within 9 days: 2 subjects; ○ Within 14 and 21 days: 154 subjects; ○ Within 22 and 50 days: 20 subjects; • Latency of lack of efficacy term reported after the second dose was known for 69 cases: <ul style="list-style-type: none"> ○ Within 0 and 7 days: 42 subjects; ○ Within 8 and 21 days: 22 subjects; ○ Within 23 and 36 days: 5 subjects. • Latency of lack of efficacy term reported in cases where the number of doses administered was not provided, was known in 409 cases: <ul style="list-style-type: none"> ○ Within 0 and 7 days after vaccination: 281 subjects. ○ Within 8 and 14 days after vaccination: 89 subjects. ○ Within 15 and 44 days after vaccination: 39 subjects. <p>According to the RSI, individuals may not be fully protected until 7 days after their second dose of vaccine, therefore for the above 1649 cases where lack of efficacy was reported after the 1st dose or the</p>		

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

Table 6. Description of Missing Information

Topic	Description
Missing Information	Post Authorization Cases Evaluation (cumulative to 28 Feb 2021) Total Number of Cases in the Reporting Period (N=42086)
	<p>2nd dose, the reported events may represent signs and symptoms of intercurrent or undiagnosed COVID-19 infection or infection in an individual who was not fully vaccinated, rather than vaccine ineffectiveness.</p> <p style="text-align: center;"><i>Vaccination failure cases (16)</i></p> <ul style="list-style-type: none"> • Vaccination failure seriousness: all serious; • Lack of efficacy term was reported in all cases after the 2nd dose; • Latency of lack of efficacy was known for 14 cases: <ul style="list-style-type: none"> ○ Within 7 and 13 days: 8 subjects; ○ Within 15 and 29 days: 6 subjects. <p>COVID-19 (10) and Asymptomatic COVID-19 (6) were the reported vaccine preventable infections that occurred in these 16 cases.</p> <p>Conclusion: No new safety signals of vaccine lack of efficacy have emerged based on a review of these cases.</p>

- a. From a total of 417 cases, 4 cases were excluded from the analysis. In 3 cases, the MAH was informed that a 33-year-old and two unspecified age pregnant female patients were scheduled to receive bnt162b2 (PT reported Off label use and Product use issue in 2 cases; Circumstance or information capable of leading to medication error in one case). One case reported the PT Morning sickness; however, pregnancy was not confirmed in this case.
- b. 558 additional cases retrieved in this dataset were excluded from the analysis; upon review, 546 cases cannot be considered true lack of efficacy cases because the PT Drug ineffective was coded but the subjects developed SARS-CoV-2 infection during the early days from the first dose (days 1 – 13); the vaccine has not had sufficient time to stimulate the immune system and, consequently, the development of a vaccine preventable disease during this time is not considered a potential lack of effect of the vaccine; in 5 cases the PT Drug ineffective was removed after data lock point (DLP) because the subjects did not develop COVID-19 infection; in 1 case, reporting Treatment failure and Transient ischaemic attack, the Lack of efficacy PT did not refer to BNT162b2 vaccine; 5 cases have been invalidated in the safety database after DLP; 1 case has been deleted from the discussion because the PTs reported Pathogen resistance and Product preparation issue were not indicative of a lack of efficacy. to be eliminated.
- c. Upon review, 31 additional cases were excluded from the analysis as the data reported (e.g. clinical details, height, weight, etc.) were not consistent with paediatric subjects
- d. Upon review, 28 additional cases were excluded from the analysis as the data reported (e.g. clinical details, height, weight, etc.) were not consistent with paediatric subjects.
- e. Different clinical outcomes may be reported for an event that occurred more than once to the same individual
- f. In 2 cases the PT Vaccination failure was replaced with Drug ineffective after DLP. Another case was not included in the discussion of the Vaccination failure cases because correct scheduling (21 days apart between the first and second dose) cannot be confirmed.

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

3.1.3. Review of Adverse Events of Special Interest (AESIs)

Please refer to [Appendix 1](#) for the list of the company's AESIs for BNT162b2.

The company's AESI list takes into consideration the lists of AESIs from the following expert groups and regulatory authorities: Brighton Collaboration (SPEAC), ACCESS protocol, US CDC (preliminary list of AESI for VAERS surveillance), MHRA (unpublished guideline).

The AESI terms are incorporated into a TME list and include events of interest due to their association with severe COVID-19 and events of interest for vaccines in general.

The AESI list is comprised of MedDRA PTs, HLTs, HLTs or MedDRA SMQs and can be changed as appropriate based on the evolving safety profile of the vaccine.

Table 7 provides a summary review of cumulative cases within AESI categories in the Pfizer safety database. This is distinct from safety signal evaluations which are conducted and included, as appropriate, in the Summary Monthly Safety Reports submitted regularly to the FDA and other Health Authorities.

Table 7. AESIs Evaluation for BNT162b2

AESIs ^a Category	Post-Marketing Cases Evaluation ^b Total Number of Cases (N=42086)
Anaphylactic Reactions <i>Search criteria: Anaphylactic reaction SMQ (Narrow and Broad, with the algorithm applied), selecting relevant cases according to BC criteria</i>	Please refer to the Risk 'Anaphylaxis' included above in Table 4 .
Cardiovascular AESIs <i>Search criteria: PTs Acute myocardial infarction; Arrhythmia; Cardiac failure; Cardiac failure acute; Cardiogenic shock; Coronary artery disease; Myocardial infarction; Postural orthostatic tachycardia syndrome; Stress cardiomyopathy; Tachycardia</i>	<ul style="list-style-type: none"> • Number of cases: 1403 (3.3% of the total PM dataset), of which 241 are medically confirmed and 1162 are non-medically confirmed; • Country of incidence: UK (268), US (233), Mexico (196), Italy (141), France (128), Germany (102), Spain (46), Greece (45), Portugal (37), Sweden (20), Ireland (17), Poland (16), Israel (13), Austria, Romania and Finland (12 each), Netherlands (11), Belgium and Norway (10 each), Czech Republic (9), Hungary and Canada (8 each), Croatia and Denmark (7 each), Iceland (5); the remaining 30 cases were distributed among 13 other countries; • Subjects' gender: female (1076), male (291) and unknown (36); • Subjects' age group (n = 1346): Adult^c (1078), Elderly^d (266) Child^e and Adolescent^f (1 each); • Number of relevant events: 1441, of which 946 serious, 495 non-serious; in the cases reporting relevant serious events; • Reported relevant PTs: Tachycardia (1098), Arrhythmia (102), Myocardial infarction (89), Cardiac failure (80), Acute myocardial infarction (41), Cardiac failure acute (11), Cardiogenic shock and Postural orthostatic tachycardia syndrome (7 each) and Coronary artery disease (6); • Relevant event onset latency (n = 1209): Range from <24 hours to 21 days, median <24 hours;

Table 7. AESIs Evaluation for BNT162b2

AESIs^a Category	Post-Marketing Cases Evaluation^b Total Number of Cases (N=42086)
	<ul style="list-style-type: none"> • Relevant event outcome^g: fatal (136), resolved/resolving (767), resolved with sequelae (21), not resolved (140) and unknown (380); <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue</p>
<p>COVID-19 AESIs <i>Search criteria: Covid-19 SMQ (Narrow and Broad) OR PTs Ageusia; Anosmia</i></p>	<ul style="list-style-type: none"> • Number of cases: 3067 (7.3% of the total PM dataset), of which 1013 are medically confirmed and 2054 are non-medically confirmed; • Country of incidence: US (1272), UK (609), Germany (360), France (161), Italy (94), Spain (69), Romania (62), Portugal (51), Poland (50), Mexico (43), Belgium (42), Israel (41), Sweden (30), Austria (27), Greece (24), Denmark (18), Czech Republic and Hungary (17 each), Canada (12), Ireland (11), Slovakia (9), Latvia and United Arab Emirates (6 each); the remaining 36 cases were distributed among 16 other different countries; • Subjects' gender: female (1650), male (844) and unknown (573); • Subjects' age group (n= 1880): Adult (1315), Elderly (560), Infant^h and Adolescent (2 each), Child (1); • Number of relevant events: 3359, of which 2585 serious, 774 non-serious; • Most frequently reported relevant PTs (>1 occurrence): COVID-19 (1927), SARS-CoV-2 test positive (415), Suspected COVID-19 (270), Ageusia (228), Anosmia (194), SARS-CoV-2 antibody test negative (83), Exposure to SARS-CoV-2 (62), SARS-CoV-2 antibody test positive (53), COVID-19 pneumonia (51), Asymptomatic COVID-19 (31), Coronavirus infection (13), Occupational exposure to SARS-CoV-2 (11), SARS-CoV-2 test false positive (7), Coronavirus test positive (6), SARS-CoV-2 test negative (3) SARS-CoV-2 antibody test (2); • Relevant event onset latency (n = 2070): Range from <24 hours to 374 days, median 5 days; • Relevant event outcome: fatal (136), not resolved (547), resolved/resolving (558), resolved with sequelae (9) and unknown (2110). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue</p>
<p>Dermatological AESIs <i>Search criteria: PT Chillblains; Erythema multiforme</i></p>	<ul style="list-style-type: none"> • Number of cases: 20 cases (0.05% of the total PM dataset), of which 15 are medically confirmed and 5 are non-medically confirmed; • Country of incidence: UK (8), France and Poland (2 each), and the remaining 8 cases were distributed among 8 other different countries; • Subjects' gender: female (17) male and unknown (1 each); • Subjects' age group (n=19): Adult (18), Elderly (1); • Number of relevant events: 20 events, 16 serious, 4 non-serious

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

Table 7. AESIs Evaluation for BNT162b2

AESIs^a Category	Post-Marketing Cases Evaluation^b Total Number of Cases (N=42086)
	<ul style="list-style-type: none"> • Reported relevant PTs: Erythema multiforme (13) and Chillblains (7) • Relevant event onset latency (n = 18): Range from <24 hours to 17 days, median 3 days; • Relevant event outcome: resolved/resolving (7), not resolved (8) and unknown (6). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue.</p>
<p>Haematological AESIs <i>Search criteria: Leukopenias NEC (HLT) (Primary Path) OR Neutropenias (HLT) (Primary Path) OR PTs Immune thrombocytopenia, Thrombocytopenia OR SMQ Haemorrhage terms (excl laboratory terms</i></p>	<ul style="list-style-type: none"> • Number of cases: 932 (2.2 % of the total PM dataset), of which 524 medically confirmed and 408 non-medically confirmed; • Country of incidence: UK (343), US (308), France (50), Germany (43), Italy (37), Spain (27), Mexico and Poland (13 each), Sweden (10), Israel (9), Netherlands (8), Denmark, Finland, Portugal and Ireland (7 each), Austria and Norway (6 each), Croatia (4), Greece, Belgium, Hungary and Switzerland (3 each), Cyprus, Latvia and Serbia (2 each); the remaining 9 cases originated from 9 different countries; • Subjects' gender (n=898): female (676) and male (222); • Subjects' age group (n=837): Adult (543), Elderly (293), Infant (1); • Number of relevant events: 1080, of which 681 serious, 399 non-serious; • Most frequently reported relevant PTs (≥15 occurrences) include: Epistaxis (127), Contusion (112), Vaccination site bruising (96), Vaccination site haemorrhage (51), Petechiae (50), Haemorrhage (42), Haematochezia (34), Thrombocytopenia (33), Vaccination site haematoma (32), Conjunctival haemorrhage and Vaginal haemorrhage (29 each), Haematoma, Haemoptysis and Menorrhagia (27 each), Haematemesis (25), Eye haemorrhage (23), Rectal haemorrhage (22), Immune thrombocytopenia (20), Blood urine present (19), Haematuria, Neutropenia and Purpura (16 each) Diarrhoea haemorrhagic (15); • Relevant event onset latency (n = 787): Range from <24 hours to 33 days, median = 1 day; • Relevant event outcome: fatal (34), resolved/resolving (393), resolved with sequelae (17), not resolved (267) and unknown (371). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue</p>
<p>Hepatic AESIs <i>Search criteria: Liver related investigations, signs and symptoms (SMQ) (Narrow and Broad) OR PT Liver injury</i></p>	<ul style="list-style-type: none"> • Number of cases: 70 cases (0.2% of the total PM dataset), of which 54 medically confirmed and 16 non-medically confirmed; • Country of incidence: UK (19), US (14), France (7), Italy (5), Germany (4), Belgium, Mexico and Spain (3 each), Austria, and Iceland (2 each); the remaining 8 cases originated from 8 different countries; • Subjects' gender: female (43), male (26) and unknown (1); • Subjects' age group (n=64): Adult (37), Elderly (27);

Table 7. AESIs Evaluation for BNT162b2

AESIs^a Category	Post-Marketing Cases Evaluation^b Total Number of Cases (N=42086)
	<ul style="list-style-type: none"> • Number of relevant events: 94, of which 53 serious, 41 non-serious; • Most frequently reported relevant PTs (≥ 3 occurrences) include: Alanine aminotransferase increased (16), Transaminases increased and Hepatic pain (9 each), Liver function test increased (8), Aspartate aminotransferase increased and Liver function test abnormal (7 each), Gamma-glutamyltransferase increased and Hepatic enzyme increased (6 each), Blood alkaline phosphatase increased and Liver injury (5 each), Ascites, Blood bilirubin increased and Hypertransaminasaemia (3 each); • Relevant event onset latency (n = 57): Range from <24 hours to 20 days, median 3 days; • Relevant event outcome: fatal (5), resolved/resolving (27), resolved with sequelae (1), not resolved (14) and unknown (47). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue</p>
<p>Facial Paralysis <i>Search criteria: PTs Facial paralysis, Facial paresis</i></p>	<ul style="list-style-type: none"> • Number of cases: 449ⁱ (1.07% of the total PM dataset), 314 medically confirmed and 135 non-medically confirmed; • Country of incidence: US (124), UK (119), Italy (40), France (27), Israel (20), Spain (18), Germany (13), Sweden (11), Ireland (9), Cyprus (8), Austria (7), Finland and Portugal (6 each), Hungary and Romania (5 each), Croatia and Mexico (4 each), Canada (3), Czech Republic, Malta, Netherlands, Norway, Poland and Puerto Rico (2 each); the remaining 8 cases originated from 8 different countries; • Subjects' gender: female (295), male (133), unknown (21); • Subjects' age group (n=411): Adult (313), Elderly (96), Infant and Child (1 each); • Number of relevant events^k: 453, of which 399 serious, 54 non-serious; • Reported relevant PTs: Facial paralysis (401), Facial paresis (64); • Relevant event onset latency (n = 404): Range from <24 hours to 46 days, median 2 days; • Relevant event outcome: resolved/resolving (184), resolved with sequelae (3), not resolved (183) and unknown (97); <p>Overall Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue. Causality assessment will be further evaluated following availability of additional unblinded data from the clinical study C4591001, which will be unblinded for final analysis approximately mid-April 2021. Additionally, non-interventional post-authorisation safety studies, C4591011 and C4591012 are expected to capture data on a sufficiently large vaccinated population to detect an increased risk of Bell's palsy in vaccinated individuals. The timeline for conducting these analyses will be established based on the size of the vaccinated population captured in the study data sources by the first interim reports (due 30 June</p>

Table 7. AESIs Evaluation for BNT162b2

AESIs ^a Category	Post-Marketing Cases Evaluation ^b Total Number of Cases (N=42086)
<p>Immune-Mediated/Autoimmune AESIs</p> <p><i>Search criteria: Immune-mediated/autoimmune disorders (SMQ) (Broad and Narrow) OR Autoimmune disorders HLGT (Primary Path) OR PTs Cytokine release syndrome; Cytokine storm; Hypersensitivity</i></p>	<p>2021). Study C4591021, pending protocol endorsement by EMA, is also intended to inform this risk.</p> <ul style="list-style-type: none"> • Number of cases: 1050 (2.5 % of the total PM dataset), of which 760 medically confirmed and 290 non-medically confirmed; • Country of incidence (>10 cases): UK (267), US (257), Italy (70), France and Germany (69 each), Mexico (36), Sweden (35), Spain (32), Greece (31), Israel (21), Denmark (18), Portugal (17), Austria and Czech Republic (16 each), Canada (12), Finland (10). The remaining 74 cases were from 24 different countries. • Subjects' gender (n=682): female (526), male (156). • Subjects' age group (n=944): Adult (746), Elderly (196), Adolescent (2). • Number of relevant events: 1077, of which 780 serious, 297 non-serious. • Most frequently reported relevant PTs (>10 occurrences): Hypersensitivity (596), Neuropathy peripheral (49), Pericarditis (32), Myocarditis (25), Dermatitis (24), Diabetes mellitus and Encephalitis (16 each), Psoriasis (14), Dermatitis Bullous (13), Autoimmune disorder and Raynaud's phenomenon (11 each); • Relevant event onset latency (n = 807): Range from <24 hours to 30 days, median <24 hours. • Relevant event outcome¹: resolved/resolving (517), not resolved (215), fatal (12), resolved with sequelae (22) and unknown (312). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue</p>
<p>Musculoskeletal AESIs</p> <p><i>Search criteria: PTs Arthralgia; Arthritis; Arthritis bacterial¹; Chronic fatigue syndrome; Polyarthritits; Polyneuropathy; Post viral fatigue syndrome; Rheumatoid arthritis</i></p>	<ul style="list-style-type: none"> • Number of cases: 3600 (8.5% of the total PM dataset), of which 2045 medically confirmed and 1555 non-medically confirmed; • Country of incidence: UK (1406), US (1004), Italy (285), Mexico (236), Germany (72), Portugal (70), France (48), Greece and Poland (46), Latvia (33), Czech Republic (32), Israel and Spain (26), Sweden (25), Romania (24), Denmark (23), Finland and Ireland (19 each), Austria and Belgium (18 each), Canada (16), Netherlands (14), Bulgaria (12), Croatia and Serbia (9 each), Cyprus and Hungary (8 each), Norway (7), Estonia and Puerto Rico (6 each), Iceland and Lithuania (4 each); the remaining 21 cases originated from 11 different countries; • Subjects' gender (n=3471): female (2760), male (711); • Subjects' age group (n=3372): Adult (2850), Elderly (515), Child (4), Adolescent (2), Infant (1); • Number of relevant events: 3640, of which 1614 serious, 2026 non-serious; • Reported relevant PTs: Arthralgia (3525), Arthritis (70), Rheumatoid arthritis (26), Polyarthritits (5), Polyneuropathy, Post viral fatigue syndrome, Chronic fatigue syndrome (4 each), Arthritis bacterial (1); • Relevant event onset latency (n = 2968): Range from <24 hours to 32 days, median 1 day;

Table 7. AESIs Evaluation for BNT162b2

AESIs^a Category	Post-Marketing Cases Evaluation^b Total Number of Cases (N=42086)
	<ul style="list-style-type: none"> Relevant event outcome: resolved/resolving (1801), not resolved (959), resolved with sequelae (49), and unknown (853). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue.</p>
<p>Neurological AESIs (including demyelination)</p> <p><i>Search criteria: Convulsions (SMQ) (Broad and Narrow) OR Demyelination (SMQ) (Broad and Narrow) OR PTs Ataxia; Cataplexy; Encephalopathy; Fibromyalgia; Intracranial pressure increased; Meningitis; Meningitis aseptic; Narcolepsy</i></p>	<ul style="list-style-type: none"> Number of cases: 501 (1.2% of the total PM dataset), of which 365 medically confirmed and 136 non-medically confirmed. Country of incidence (≥9 cases): UK (157), US (68), Germany (49), Mexico (35), Italy (31), France (25), Spain (18), Poland (17), Netherlands and Israel (15 each), Sweden (9). The remaining 71 cases were from 22 different countries. Subjects' gender (n=478): female (328), male (150). Subjects' age group (n=478): Adult (329), Elderly (149); Number of relevant events: 542, of which 515 serious, 27 non-serious. Most frequently reported relevant PTs (>2 occurrences) included: Seizure (204), Epilepsy (83), Generalised tonic-clonic seizure (33), Guillain-Barre syndrome (24), Fibromyalgia and Trigeminal neuralgia (17 each), Febrile convulsion, (15), Status epilepticus (12), Aura and Myelitis transverse (11 each), Multiple sclerosis relapse and Optic neuritis (10 each), Petit mal epilepsy and Tonic convulsion (9 each), Ataxia (8), Encephalopathy and Tonic clonic movements (7 each), Foaming at mouth (5), Multiple sclerosis, Narcolepsy and Partial seizures (4 each), Bad sensation, Demyelination, Meningitis, Postictal state, Seizure like phenomena and Tongue biting (3 each); Relevant event onset latency (n = 423): Range from <24 hours to 48 days, median 1 day; Relevant events outcome: fatal (16), resolved/resolving (265), resolved with sequelae (13), not resolved (89) and unknown (161); <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue</p>
<p>Other AESIs</p> <p><i>Search criteria: Herpes viral infections (HLT) (Primary Path) OR PTs Adverse event following immunisation; Inflammation; Manufacturing laboratory analytical testing issue; Manufacturing materials issue; Manufacturing production issue; MERS-CoV test; MERS-CoV test negative; MERS-CoV test positive; Middle East respiratory syndrome; Multiple organ dysfunction syndrome; Occupational exposure to communicable disease; Patient</i></p>	<ul style="list-style-type: none"> Number of cases: 8152 (19.4% of the total PM dataset), of which 4977 were medically confirmed and 3175 non-medically confirmed; Country of incidence (> 20 occurrences): UK (2715), US (2421), Italy (710), Mexico (223), Portugal (210), Germany (207), France (186), Spain (183), Sweden (133), Denmark (127), Poland (120), Greece (95), Israel (79), Czech Republic (76), Romania (57), Hungary (53), Finland (52), Norway (51), Latvia (49), Austria (47), Croatia (42), Belgium (41), Canada (39), Ireland (34), Serbia (28), Iceland (25), Netherlands (22). The remaining 127 cases were from 21 different countries; Subjects' gender (n=7829): female (5969), male (1860); Subjects' age group (n=7479): Adult (6330), Elderly (1125), Adolescent, Child (9 each), Infant (6);

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

Table 7. AESIs Evaluation for BNT162b2

AESIs^a Category	Post-Marketing Cases Evaluation^b Total Number of Cases (N=42086)
<i>isolation; Product availability issue; Product distribution issue; Product supply issue; Pyrexia; Quarantine; SARS-CoV-1 test; SARS-CoV-1 test negative; SARS-CoV-1 test positive</i>	<ul style="list-style-type: none"> • Number of relevant events: 8241, of which 3674 serious, 4568 non-serious; • Most frequently reported relevant PTs (≥ 6 occurrences) included: Pyrexia (7666), Herpes zoster (259), Inflammation (132), Oral herpes (80), Multiple organ dysfunction syndrome (18), Herpes virus infection (17), Herpes simplex (13), Ophthalmic herpes zoster (10), Herpes ophthalmic and Herpes zoster reactivation (6 each); • Relevant event onset latency (n =6836): Range from <24 hours to 61 days, median 1 day; • Relevant events outcome: fatal (96), resolved/resolving (5008), resolved with sequelae (84), not resolved (1429) and unknown (1685). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue</p>
Pregnancy Related AESIs <i>Search criteria: PTs Amniotic cavity infection; Caesarean section; Congenital anomaly; Death neonatal; Eclampsia; Foetal distress syndrome; Low birth weight baby; Maternal exposure during pregnancy; Placenta praevia; Pre-eclampsia; Premature labour; Stillbirth; Uterine rupture; Vasa praevia</i>	For relevant cases, please refer to Table 6 , Description of Missing Information, Use in Pregnancy and While Breast Feeding
Renal AESIs <i>Search criteria: PTs Acute kidney injury; Renal failure.</i>	<ul style="list-style-type: none"> • Number of cases: 69 cases (0.17% of the total PM dataset), of which 57 medically confirmed, 12 non-medically confirmed; • Country of incidence: Germany (17), France and UK (13 each), US (6), Belgium, Italy and Spain (4 each), Sweden (2), Austria, Canada, Denmark, Finland, Luxembourg and Norway (1 each); • Subjects' gender: female (46), male (23); • Subjects' age group (n=68): Adult (7), Elderly (60), Infant (1); • Number of relevant events: 70, all serious; • Reported relevant PTs: Acute kidney injury (40) and Renal failure (30); • Relevant event onset latency (n = 42): Range from <24 hours to 15 days, median 4 days; • Relevant event outcome: fatal (23), resolved/resolving (10), not resolved (15) and unknown (22). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue.</p>
Respiratory AESIs <i>Search criteria: Lower respiratory tract infections NEC (HLT)</i>	<ul style="list-style-type: none"> • Number of cases: 130 cases (0.3% of the total PM dataset), of which 107 medically confirmed;

Table 7. AESIs Evaluation for BNT162b2

AESIs^a Category	Post-Marketing Cases Evaluation^b Total Number of Cases (N=42086)
<p><i>(Primary Path) OR Respiratory failures (excl neonatal) (HLT)</i> <i>(Primary Path) OR Viral lower respiratory tract infections (HLT)</i> <i>(Primary Path) OR PTs: Acute respiratory distress syndrome; Endotracheal intubation; Hypoxia; Pulmonary haemorrhage; Respiratory disorder; Severe acute respiratory syndrome</i></p>	<ul style="list-style-type: none"> • Countries of incidence: United Kingdom (20), France (18), United States (16), Germany (14), Spain (13), Belgium and Italy (9), Denmark (8), Norway (5), Czech Republic, Iceland (3 each); the remaining 12 cases originated from 8 different countries. • Subjects' gender (n=130): female (72), male (58). • Subjects's age group (n=126): Elderly (78), Adult (47), Adolescent (1). • Number of relevant events: 137, of which 126 serious, 11 non-serious; • Reported relevant PTs: Respiratory failure (44), Hypoxia (42), Respiratory disorder (36), Acute respiratory distress syndrome (10), Chronic respiratory syndrome (3), Severe acute respiratory syndrome (2). • Relevant event onset latency (n=102): range from < 24 hours to 18 days, median 1 day; • Relevant events outcome: fatal (41), Resolved/resolving (47), not recovered (18) and unknown (31). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue.</p>
<p>Thromboembolic Events <i>Search criteria: Embolism and thrombosis (HLGT) (Primary Path), excluding PTs reviewed as Stroke AESIs, OR PTs Deep vein thrombosis; Disseminated intravascular coagulation; Embolism; Embolism venous; Pulmonary embolism</i></p>	<ul style="list-style-type: none"> • Number of cases: 151 (0.3% of the total PM dataset), of which 111 medically confirmed and 40 non-medically confirmed; • Country of incidence: UK (34), US (31), France (20), Germany (15), Italy and Spain (6 each), Denmark and Sweden (5 each), Austria, Belgium and Israel (3 each), Canada, Cyprus, Netherlands and Portugal (2 each); the remaining 12 cases originated from 12 different countries; • Subjects' gender (n= 144): female (89), male (55); • Subjects' age group (n=136): Adult (66), Elderly (70); • Number of relevant events: 168, of which 165 serious, 3 non-serious; • Most frequently reported relevant PTs (>1 occurrence) included: Pulmonary embolism (60), Thrombosis (39), Deep vein thrombosis (35), Thrombophlebitis superficial (6), Venous thrombosis limb (4), Embolism, Microembolism, Thrombophlebitis and Venous thrombosis (3 each) Blue toe syndrome (2); • Relevant event onset latency (n = 124): Range from <24 hours to 28 days, median 4 days; • Relevant event outcome: fatal (18), resolved/resolving (54), resolved with sequelae (6), not resolved (49) and unknown (42). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue.</p>
<p>Stroke <i>Search criteria: HLT Central nervous system haemorrhages and cerebrovascular accidents</i></p>	<ul style="list-style-type: none"> • Number of cases: 275 (0.6% of the total PM dataset), of which 180 medically confirmed and 95 non-medically confirmed; • Country of incidence: UK (81), US (66), France (32), Germany (21), Norway (14), Netherlands and Spain (11 each), Sweden (9),

Table 7. AESIs Evaluation for BNT162b2

AESIs^a Category	Post-Marketing Cases Evaluation^b Total Number of Cases (N=42086)
<p><i>(Primary Path) OR HLT Cerebrovascular venous and sinus thrombosis (Primary Path)</i></p>	<p>Israel (6), Italy (5), Belgium (3), Denmark, Finland, Poland and Switzerland (2 each); the remaining 8 cases originated from 8 different countries;</p> <ul style="list-style-type: none"> • Subjects' gender (n= 273): female (182), male (91); • Subjects' age group (n=265): Adult (59), Elderly (205), Child^m (1); • Number of relevant events: 300, all serious; • Most frequently reported relevant PTs (>1 occurrence) included: <ul style="list-style-type: none"> ○ PTs indicative of Ischaemic stroke: Cerebrovascular accident (160), Ischaemic stroke (41), Cerebral infarction (15), Cerebral ischaemia, Cerebral thrombosis, Cerebral venous sinus thrombosis, Ischaemic cerebral infarction and Lacunal infarction (3 each) Basal ganglia stroke, Cerebellar infarction and Thrombotic stroke (2 each); ○ PTs indicative of Haemorrhagic stroke: Cerebral haemorrhage (26), Haemorrhagic stroke (11), Haemorrhage intracranial and Subarachnoid haemorrhage (5 each), Cerebral haematoma (4), Basal ganglia haemorrhage and Cerebellar haemorrhage (2 each); • Relevant event onset latency (n = 241): Range from <24 hours to 41 days, median 2 days; • Relevant event outcome: fatal and resolved/resolving (61 each), resolved with sequelae (10), not resolved (85) and unknown (83). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue.</p>
<p>Vasculitic Events <i>Search criteria: Vasculitides HLT</i></p>	<ul style="list-style-type: none"> • Number of cases: 32 cases (0.08% of the total PM dataset), of which 26 medically confirmed and 6 non-medically confirmed; • Country of incidence: UK (13), France (4), Portugal, US and Spain (3 each), Cyprus, Germany, Hungary, Italy and Slovakia and Costa rica (1 each); • Subjects' gender: female (26), male (6); • Subjects' age group (n=31): Adult (15), Elderly (16); • Number of relevant events: 34, of which 25 serious, 9 non-serious; • Reported relevant PTs: Vasculitis (14), Cutaneous vasculitis and Vasculitic rash (4 each), (3), Giant cell arteritis and Peripheral ischaemia (3 each), Behcet's syndrome and Hypersensitivity vasculitis (2 each) Palpable purpura, and Takayasu's arteritis (1 each); • Relevant event onset latency (n = 25): Range from <24 hours to 19 days, median 3 days; • Relevant event outcome: fatal (1), resolved/resolving (13), not resolved (12) and unknown (8). <p>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue</p>

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

Table 7. AESIs Evaluation for BNT162b2

AESIs ^a Category	Post-Marketing Cases Evaluation ^b Total Number of Cases (N=42086)
--------------------------------	---

- a. For the complete list of the AESIs, please refer to Appendix 5;
- b. Please note that this corresponds to evidence from post-EUA/conditional marketing authorisation approval data sources;
- c. Subjects with age ranged between 18 and 64 years;
- d. Subjects with age equal to or above 65 years;
- e. Subjects with age ranged between 2 and 11 years;
- f. Subjects with age ranged between 12 and less than 18 years;
- g. Multiple episodes of the same PT event were reported with a different clinical outcome within some cases hence the sum of the events outcome exceeds the total number of PT events;
- h. Subjects with age ranged between 1 (28 days) and 23 months;
- i. Twenty-four additional cases were excluded from the analysis as they were not cases of peripheral facial nerve palsy because they described other disorders (stroke, cerebral haemorrhage or transient ischaemic attack); 1 case was excluded from the analysis because it was invalid due to an unidentifiable reporter;
- j. This UK case report received from the UK MHRA described a 1-year-old subject who received the vaccine, and had left postauricular ear pain that progressed to left-sided Bell’s palsy 1 day following vaccination that had not resolved at the time of the report;
- k. If a case included both PT Facial paresis and PT Facial paralysis, only the PT Facial paralysis was considered in the descriptions of the events as it is most clinically important;
- l. Multiple episodes of the same PT event were reported with a different clinical outcome within some cases hence the sum of the events outcome exceeds the total number of PT events
- m. This UK case report received from the UK MHRA described a 7-year-old female subject who received the vaccine and had stroke (unknown outcome); no follow-up is possible for clarification.
- n. This PT not included in the AESIs/TME list was included in the review as relevant for ACCESS protocol criteria;

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

3.1.4. Medication error

Cases potentially indicative of medication errors¹ that cumulatively occurred are summarized below.

- Number of relevant medication error cases: 2056² (4.9%) of which 1569 (3.7%) are medically confirmed.
- Number of relevant events: 2792
- Top 10 countries of incidence:
 - US (1201), France (171), UK (138), Germany (88), Czech Republic (87), Sweden (49), Israel (45), Italy (42), Canada (35), Romania (33), Finland (21), Portugal (20), Norway (14), Puerto Rico (13), Poland (12), Austria and Spain (10 each).

Medication error case outcomes:

- Fatal (7)³,
- Recovered/recovering (354, of which 4 are serious),
- Recovered with sequelae (8, of which 3 serious)

¹ MedDRA (version 23.1) Higher Level Terms: Accidental exposures to product; Product administration errors and issues; Product confusion errors and issues; Product dispensing errors and issues; Product label issues; Product monitoring errors and issues; Product preparation errors and issues; Product selection errors and issues; Product storage errors and issues in the product use system; Product transcribing errors and communication issues, OR Preferred Terms: Accidental poisoning; Circumstance or information capable of leading to device use error; Circumstance or information capable of leading to medication error; Contraindicated device used; Deprescribing error; Device use error; Dose calculation error; Drug titration error; Expired device used; Exposure via direct contact; Exposure via eye contact; Exposure via mucosa; Exposure via skin contact; Failure of child resistant product closure; Inadequate aseptic technique in use of product; Incorrect disposal of product; Intercepted medication error; Intercepted product prescribing error; Medication error; Multiple use of single-use product; Product advertising issue; Product distribution issue; Product prescribing error; Product prescribing issue; Product substitution error; Product temperature excursion issue; Product use in unapproved therapeutic environment; Radiation underdose; Underdose; Unintentional medical device removal; Unintentional use for unapproved indication; Vaccination error; Wrong device used; Wrong dosage form; Wrong dosage formulation; Wrong dose; Wrong drug; Wrong patient; Wrong product procured; Wrong product stored; Wrong rate; Wrong route; Wrong schedule; Wrong strength; Wrong technique in device usage process; Wrong technique in product usage process.

² Thirty-five (35) cases were excluded from the analysis because describing medication errors occurring in an unspecified number of individuals or describing medication errors occurring with co suspects were determined to be non-contributory.

³ All the medication errors reported in these cases were assessed as non-serious occurrences with an unknown outcome; based on the available information including the causes of death, the relationship between the medication error and the death is weak. .

- Not recovered (189, of which 84 are serious),
- Unknown (1498, of which 33 are serious).

1371 cases reported only MEs without any associated clinical adverse event. The PTs most frequently reported (≥ 12 occurrences) were: Poor quality product administered (539), Product temperature excursion issue (253), Inappropriate schedule of product administration (225), Product preparation error (206), Underdose (202), Circumstance or information capable of leading to medication error (120), Product preparation issue (119), Wrong technique in product usage process (76), Incorrect route of product administration (66), Accidental overdose (33), Product administered at inappropriate site (27), Incorrect dose administered and Accidental exposure to the product (25 each), Exposure via skin contact (22), Wrong product administered (17), Incomplete course of vaccination, and Product administration error (14 each) Product administered to patient of inappropriate age (12).

In 685 cases, there were co-reported AEs. The most frequently co-associated AEs (> 40 occurrences) were: Headache (187), Pyrexia (161), Fatigue (135), Chills (127), Pain (107), Vaccination site pain (100), Nausea (89), Myalgia (88), Pain in extremity (85) Arthralgia (68), Off label use (57), Dizziness (52), Lymphadenopathy (47), Asthenia (46) and Malaise (41). These cases are summarized in Table 8.

Table 8. ME PTs by seriousness with or without harm co-association (Through 28 February 2021)

ME PTs	Serious		Non-Serious	
	With Harm	Without Harm	With Harm	Without Harm
Accidental exposure to product	0	0	0	5
Accidental overdose	4	1	9	6
Booster dose missed	0	0	0	1
Circumstance or information capable of leading to medication error	0	0	5	11
Contraindicated product administered	1	0	0	2
Expired product administered	0	0	0	2
Exposure via skin contact	0	0	0	5
Inappropriate schedule of product administration	0	2	8	264
Incorrect dose administered	1	1	0	0

Table 8. ME PTs by seriousness with or without harm co-association (Through 28 February 2021)

ME PTs	Serious		Non-Serious	
	With Harm	Without Harm	With Harm	Without Harm
Incorrect route of product administration	2	6	16	127
Lack of vaccination site rotation	1	0	0	0
Medication error	0	0	0	1
Poor quality product administered	1	0	0	34
Product administered at inappropriate site	2	1	13	29
Product administered to patient of inappropriate age	0	4	0	40
Product administration error	1	0	0	3
Product dose omission issue	0	1	0	3
Product preparation error	1	0	4	11
Product preparation issue	1	1	0	14

Overall, there were 68 cases with co-reported AEs reporting Harm and 599 cases with co-reported AEs without harm. Additionally, Intercepted medication errors was reported in 1 case (PTs Malaise, clinical outcome unknow) and Potential medication errors were reported in 17 cases.

4. DISCUSSION

Pfizer performs frequent and rigorous signal detection on BNT162b2 cases. The findings of these signal detection analyses are consistent with the known safety profile of the vaccine. This cumulative analysis to support the Biologics License Application for BNT162b2, is an integrated analysis of post-authorization safety data, from U.S. and foreign experience, focused on Important Identified Risks, Important Potential Risks, and areas of Important Missing Information identified in the Pharmacovigilance Plan, as well as adverse events of special interest and vaccine administration errors (whether or not associated with an adverse event). The data do not reveal any novel safety concerns or risks requiring label changes and support a favorable benefit risk profile of to the BNT162b2 vaccine.

5. SUMMARY AND CONCLUSION

Review of the available data for this cumulative PM experience, confirms a favorable benefit: risk balance for BNT162b2.

Pfizer will continue routine pharmacovigilance activities on behalf of BioNTech according to the Pharmacovigilance Agreement in place, in order to assure patient safety and will inform the Agency if an evaluation of the safety data yields significant new information for BNT162b2.

APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST

1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5'nucleotidase increased;Acoustic neuritis;Acquired C1 inhibitor deficiency;Acquired epidermolysis bullosa;Acquired epileptic aphasia;Acute cutaneous lupus erythematosus;Acute disseminated encephalomyelitis;Acute encephalitis with refractory, repetitive partial seizures;Acute febrile neutrophilic dermatosis;Acute flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acute haemorrhagic oedema of infancy;Acute kidney injury;Acute macular outer retinopathy;Acute motor axonal neuropathy;Acute motor-sensory axonal neuropathy;Acute myocardial infarction;Acute respiratory distress syndrome;Acute respiratory failure;Addison's disease;Administration site thrombosis;Administration site vasculitis;Adrenal thrombosis;Adverse event following immunisation;Ageusia;Agranulocytosis;Air embolism;Alanine aminotransferase abnormal;Alanine aminotransferase increased;Alcoholic seizure;Allergic bronchopulmonary mycosis;Allergic oedema;Alloimmune hepatitis;Alopecia areata;Alpers disease;Alveolar proteinosis;Ammonia abnormal;Ammonia increased;Amniotic cavity infection;Amygdalohippocampectomy;Amyloid arthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic reaction;Anaphylactic shock;Anaphylactic transfusion reaction;Anaphylactoid reaction;Anaphylactoid shock;Anaphylactoid syndrome of pregnancy;Angioedema;Angiopathic neuropathy;Ankylosing spondylitis;Anosmia;Antiacetylcholine receptor antibody positive;Anti-actin antibody positive;Anti-aquaporin-4 antibody positive;Anti-basal ganglia antibody positive;Anti-cyclic citrullinated peptide antibody positive;Anti-epithelial antibody positive;Anti-erythrocyte antibody positive;Anti-exosome complex antibody positive;Anti-GAD antibody negative;Anti-GAD antibody positive;Anti-ganglioside antibody positive;Antigliadin antibody positive;Anti-glomerular basement membrane antibody positive;Anti-glomerular basement membrane disease;Anti-glycyl-tRNA synthetase antibody positive;Anti-HLA antibody test positive;Anti-IA2 antibody positive;Anti-insulin antibody increased;Anti-insulin antibody positive;Anti-insulin receptor antibody increased;Anti-insulin receptor antibody positive;Anti-interferon antibody negative;Anti-interferon antibody positive;Anti-islet cell antibody positive;Antimitochondrial antibody positive;Anti-muscle specific kinase antibody positive;Anti-myelin-associated glycoprotein antibodies positive;Anti-myelin-associated glycoprotein associated polyneuropathy;Antimyocardial antibody positive;Anti-neuronal antibody positive;Antineutrophil cytoplasmic antibody increased;Antineutrophil cytoplasmic antibody positive;Anti-neutrophil cytoplasmic antibody positive vasculitis;Anti-NMDA antibody positive;Antinuclear antibody increased;Antinuclear antibody positive;Antiphospholipid antibodies positive;Antiphospholipid syndrome;Anti-platelet antibody positive;Anti-prothrombin antibody positive;Antiribosomal P antibody positive;Anti-RNA polymerase III antibody positive;Anti-saccharomyces cerevisiae antibody test positive;Anti-sperm antibody positive;Anti-SRP antibody positive;Antisynthetase syndrome;Anti-thyroid antibody positive;Anti-transglutaminase antibody increased;Anti-VGCC antibody positive;Anti-VGKC antibody positive;Anti-vimentin antibody positive;Antiviral prophylaxis;Antiviral treatment;Anti-zinc transporter 8 antibody positive;Aortic embolus;Aortic thrombosis;Aortitis;Aplasia pure red cell;Aplastic anaemia;Application site thrombosis;Application site vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypass thrombosis;Arterial thrombosis;Arteriovenous fistula thrombosis;Arteriovenous graft site stenosis;Arteriovenous graft thrombosis;Arteritis;Arteritis

coronary;Arthralgia;Arthritis;Arthritis enteropathic;Ascites;Aseptic cavernous sinus thrombosis;Aspartate aminotransferase abnormal;Aspartate aminotransferase increased;Aspartate-glutamate-transporter deficiency;AST to platelet ratio index increased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID-19;Ataxia;Atheroembolism;Atonic seizures;Atrial thrombosis;Atrophic thyroiditis;Atypical benign partial epilepsy;Atypical pneumonia;Aura;Autoantibody positive;Autoimmune anaemia;Autoimmune aplastic anaemia;Autoimmune arthritis;Autoimmune blistering disease;Autoimmune cholangitis;Autoimmune colitis;Autoimmune demyelinating disease;Autoimmune dermatitis;Autoimmune disorder;Autoimmune encephalopathy;Autoimmune endocrine disorder;Autoimmune enteropathy;Autoimmune eye disorder;Autoimmune haemolytic anaemia;Autoimmune heparin-induced thrombocytopenia;Autoimmune hepatitis;Autoimmune hyperlipidaemia;Autoimmune hypothyroidism;Autoimmune inner ear disease;Autoimmune lung disease;Autoimmune lymphoproliferative syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmune nephritis;Autoimmune neuropathy;Autoimmune neutropenia;Autoimmune pancreatitis;Autoimmune pancytopenia;Autoimmune pericarditis;Autoimmune retinopathy;Autoimmune thyroid disorder;Autoimmune thyroiditis;Autoimmune uveitis;Autoinflammation with infantile enterocolitis;Autoinflammatory disease;Automatism epileptic;Autonomic nervous system imbalance;Autonomic seizure;Axial spondyloarthritis;Axillary vein thrombosis;Axonal and demyelinating polyneuropathy;Axonal neuropathy;Bacterascites;Baltic myoclonic epilepsy;Band sensation;Basedow's disease;Basilar artery thrombosis;Basophilopenia;B-cell aplasia;Behcet's syndrome;Benign ethnic neutropenia;Benign familial neonatal convulsions;Benign familial pemphigus;Benign rolandic epilepsy;Beta-2 glycoprotein antibody positive;Bickerstaff's encephalitis;Bile output abnormal;Bile output decreased;Biliary ascites;Bilirubin conjugated abnormal;Bilirubin conjugated increased;Bilirubin urine present;Biopsy liver abnormal;Biotinidase deficiency;Birdshot chorioretinopathy;Blood alkaline phosphatase abnormal;Blood alkaline phosphatase increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood bilirubin unconjugated increased;Blood cholinesterase abnormal;Blood cholinesterase decreased;Blood pressure decreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue toe syndrome;Brachiocephalic vein thrombosis;Brain stem embolism;Brain stem thrombosis;Bromosulphthalein test abnormal;Bronchial oedema;Bronchitis;Bronchitis mycoplasmal;Bronchitis viral;Bronchopulmonary aspergillosis allergic;Bronchospasm;Budd-Chiari syndrome;Bulbar palsy;Butterfly rash;C1q nephropathy;Caesarean section;Calcium embolism;Capillaritis;Caplan's syndrome;Cardiac amyloidosis;Cardiac arrest;Cardiac failure;Cardiac failure acute;Cardiac sarcoidosis;Cardiac ventricular thrombosis;Cardiogenic shock;Cardiolipin antibody positive;Cardiopulmonary failure;Cardio-respiratory arrest;Cardio-respiratory distress;Cardiovascular insufficiency;Carotid arterial embolus;Carotid artery thrombosis;Cataplexy;Catheter site thrombosis;Catheter site vasculitis;Cavernous sinus thrombosis;CDKL5 deficiency disorder;CEC syndrome;Cement embolism;Central nervous system lupus;Central nervous system vasculitis;Cerebellar artery thrombosis;Cerebellar embolism;Cerebral amyloid angiopathy;Cerebral arteritis;Cerebral artery embolism;Cerebral artery thrombosis;Cerebral gas embolism;Cerebral microembolism;Cerebral septic infarct;Cerebral thrombosis;Cerebral venous sinus thrombosis;Cerebral venous thrombosis;Cerebrospinal thrombotic

tamponade;Cerebrovascular accident;Change in seizure presentation;Chest discomfort;Child-Pugh-Turcotte score abnormal;Child-Pugh-Turcotte score increased;Chillblains;Choking;Choking sensation;Cholangitis sclerosing;Chronic autoimmune glomerulonephritis;Chronic cutaneous lupus erythematosus;Chronic fatigue syndrome;Chronic gastritis;Chronic inflammatory demyelinating polyradiculoneuropathy;Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids;Chronic recurrent multifocal osteomyelitis;Chronic respiratory failure;Chronic spontaneous urticaria;Circulatory collapse;Circumoral oedema;Circumoral swelling;Clinically isolated syndrome;Clonic convulsion;Coeliac disease;Cogan's syndrome;Cold agglutinins positive;Cold type haemolytic anaemia;Colitis;Colitis erosive;Colitis herpes;Colitis microscopic;Colitis ulcerative;Collagen disorder;Collagen-vascular disease;Complement factor abnormal;Complement factor C1 decreased;Complement factor C2 decreased;Complement factor C3 decreased;Complement factor C4 decreased;Complement factor decreased;Computerised tomogram liver abnormal;Concentric sclerosis;Congenital anomaly;Congenital bilateral perisylvian syndrome;Congenital herpes simplex infection;Congenital myasthenic syndrome;Congenital varicella infection;Congestive hepatopathy;Convulsion in childhood;Convulsions local;Convulsive threshold lowered;Coombs positive haemolytic anaemia;Coronary artery disease;Coronary artery embolism;Coronary artery thrombosis;Coronary bypass thrombosis;Coronavirus infection;Coronavirus test;Coronavirus test negative;Coronavirus test positive;Corpus callosotomy;Cough;Cough variant asthma;COVID-19;COVID-19 immunisation;COVID-19 pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranial nerve disorder;Cranial nerve palsies multiple;Cranial nerve paralysis;CREST syndrome;Crohn's disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal band present;CSWS syndrome;Cutaneous amyloidosis;Cutaneous lupus erythematosus;Cutaneous sarcoidosis;Cutaneous vasculitis;Cyanosis;Cyclic neutropenia;Cystitis interstitial;Cytokine release syndrome;Cytokine storm;De novo purine synthesis inhibitors associated acute inflammatory syndrome;Death neonatal;Deep vein thrombosis;Deep vein thrombosis postoperative;Deficiency of bile secretion;Deja vu;Demyelinating polyneuropathy;Demyelination;Dermatitis;Dermatitis bullous;Dermatitis herpetiformis;Dermatomyositis;Device embolisation;Device related thrombosis;Diabetes mellitus;Diabetic ketoacidosis;Diabetic mastopathy;Dialysis amyloidosis;Dialysis membrane reaction;Diastolic hypotension;Diffuse vasculitis;Digital pitting scar;Disseminated intravascular coagulation;Disseminated intravascular coagulation in newborn;Disseminated neonatal herpes simplex;Disseminated varicella;Disseminated varicella zoster vaccine virus infection;Disseminated varicella zoster virus infection;DNA antibody positive;Double cortex syndrome;Double stranded DNA antibody positive;Dreamy state;Dressler's syndrome;Drop attacks;Drug withdrawal convulsions;Dyspnoea;Early infantile epileptic encephalopathy with burst-suppression;Eclampsia;Eczema herpeticum;Embolia cutis medicamentosa;Embolic cerebellar infarction;Embolic cerebral infarction;Embolic pneumonia;Embolic stroke;Embolism;Embolism arterial;Embolism venous;Encephalitis;Encephalitis allergic;Encephalitis autoimmune;Encephalitis brain stem;Encephalitis haemorrhagic;Encephalitis periaxialis diffusa;Encephalitis post immunisation;Encephalomyelitis;Encephalopathy;Endocrine disorder;Endocrine ophthalmopathy;Endotracheal intubation;Enteritis;Enteritis leukopenic;Enterobacter pneumonia;Enterocolitis;Enteropathic spondylitis;Eosinopenia;Eosinophilic

fasciitis;Eosinophilic granulomatosis with polyangiitis;Eosinophilic oesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy with myoclonic-atonic seizures;Epileptic aura;Epileptic psychosis;Erythema;Erythema induratum;Erythema multiforme;Erythema nodosum;Evans syndrome;Exanthema subitum;Expanded disability status scale score decreased;Expanded disability status scale score increased;Exposure to communicable disease;Exposure to SARS-CoV-2;Eye oedema;Eye pruritus;Eye swelling;Eyelid oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial dystonic seizure;Fat embolism;Febrile convulsion;Febrile infection-related epilepsy syndrome;Febrile neutropenia;Felty's syndrome;Femoral artery embolism;Fibrillary glomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal cortical resection;Focal dyscognitive seizures;Foetal distress syndrome;Foetal placental thrombosis;Foetor hepaticus;Foreign body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetes mellitus;Galactose elimination capacity test abnormal;Galactose elimination capacity test decreased;Gamma-glutamyltransferase abnormal;Gamma-glutamyltransferase increased;Gastritis herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised onset non-motor seizure;Generalised tonic-clonic seizure;Genital herpes;Genital herpes simplex;Genital herpes zoster;Giant cell arteritis;Glomerulonephritis;Glomerulonephritis membranoproliferative;Glomerulonephritis membranous;Glomerulonephritis rapidly progressive;Glossopharyngeal nerve paralysis;Glucose transporter type 1 deficiency syndrome;Glutamate dehydrogenase increased;Glycocholic acid increased;GM2 gangliosidosis;Goodpasture's syndrome;Graft thrombosis;Granulocytopenia;Granulocytopenia neonatal;Granulomatosis with polyangiitis;Granulomatous dermatitis;Grey matter heterotopia;Guanase increased;Guillain-Barre syndrome;Haemolytic anaemia;Haemophagocytic lymphohistiocytosis;Haemorrhage;Haemorrhagic ascites;Haemorrhagic disorder;Haemorrhagic pneumonia;Haemorrhagic varicella syndrome;Haemorrhagic vasculitis;Hantavirus pulmonary infection;Hashimoto's encephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein purpura;Henoch-Schonlein purpura nephritis;Hepaplastin abnormal;Hepaplastin decreased;Heparin-induced thrombocytopenia;Hepatic amyloidosis;Hepatic artery embolism;Hepatic artery flow decreased;Hepatic artery thrombosis;Hepatic enzyme abnormal;Hepatic enzyme decreased;Hepatic enzyme increased;Hepatic fibrosis marker abnormal;Hepatic fibrosis marker increased;Hepatic function abnormal;Hepatic hydrothorax;Hepatic hypertrophy;Hepatic hypoperfusion;Hepatic lymphocytic infiltration;Hepatic mass;Hepatic pain;Hepatic sequestration;Hepatic vascular resistance increased;Hepatic vascular thrombosis;Hepatic vein embolism;Hepatic vein thrombosis;Hepatic venous pressure gradient abnormal;Hepatic venous pressure gradient increased;Hepatitis;Hepatobiliary scan abnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema with C1 esterase inhibitor deficiency;Herpes dermatitis;Herpes gestationis;Herpes oesophagitis;Herpes ophthalmic;Herpes pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplex cervicitis;Herpes simplex colitis;Herpes simplex encephalitis;Herpes simplex gastritis;Herpes simplex hepatitis;Herpes simplex meningitis;Herpes simplex meningoencephalitis;Herpes simplex meningomyelitis;Herpes simplex necrotising retinopathy;Herpes simplex oesophagitis;Herpes simplex otitis externa;Herpes simplex pharyngitis;Herpes simplex pneumonia;Herpes simplex reactivation;Herpes simplex sepsis;Herpes simplex viraemia;Herpes simplex virus conjunctivitis neonatal;Herpes simplex visceral;Herpes virus

infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infection neurological;Herpes zoster meningitis;Herpes zoster meningoencephalitis;Herpes zoster meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotising retinopathy;Herpes zoster oticus;Herpes zoster pharyngitis;Herpes zoster reactivation;Herpetic radiculopathy;Histone antibody positive;Hoigne's syndrome;Human herpesvirus 6 encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infection reactivation;Human herpesvirus 7 infection;Human herpesvirus 8 infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia benign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivity vasculitis;Hyperthyroidism;Hypertransaminaemia;Hyperventilation;Hypoalbuminaemia;Hypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossal nerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensive crisis;Hypothenar hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4 lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;IIIrd nerve paralysis;IIIrd nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immune-mediated adverse reaction;Immune-mediated cholangitis;Immune-mediated cholestasis;Immune-mediated cytopenia;Immune-mediated encephalitis;Immune-mediated encephalopathy;Immune-mediated endocrinopathy;Immune-mediated enterocolitis;Immune-mediated gastritis;Immune-mediated hepatic disorder;Immune-mediated hepatitis;Immune-mediated hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediated myocarditis;Immune-mediated myositis;Immune-mediated nephritis;Immune-mediated neuropathy;Immune-mediated pancreatitis;Immune-mediated pneumonitis;Immune-mediated renal disorder;Immune-mediated thyroiditis;Immune-mediated uveitis;Immunoglobulin G4 related disease;Immunoglobulins abnormal;Implant site thrombosis;Inclusion body myositis;Infantile genetic agranulocytosis;Infantile spasms;Infected vasculitis;Infective thrombosis;Inflammation;Inflammatory bowel disease;Infusion site thrombosis;Infusion site vasculitis;Injection site thrombosis;Injection site urticaria;Injection site vasculitis;Instillation site thrombosis;Insulin autoimmune syndrome;Interstitial granulomatous dermatitis;Interstitial lung disease;Intracardiac mass;Intracardiac thrombus;Intracranial pressure increased;Intrapericardial thrombosis;Intrinsic factor antibody abnormal;Intrinsic factor antibody positive;IPEX syndrome;Irregular breathing;IRVAN syndrome;IVth nerve paralysis;IVth nerve paresis;JC polyomavirus test positive;JC virus CSF test positive;Jeavons syndrome;Jugular vein embolism;Jugular vein thrombosis;Juvenile idiopathic arthritis;Juvenile myoclonic epilepsy;Juvenile polymyositis;Juvenile psoriatic arthritis;Juvenile spondyloarthritis;Kaposi sarcoma inflammatory cytokine syndrome;Kawasaki's disease;Kayser-Fleischer ring;Keratoderma blenorrhagica;Ketosis-prone diabetes mellitus;Kounis syndrome;Lafora's myoclonic epilepsy;Lamb's excrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal rheumatoid arthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in adults;LE cells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase increased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenia neonatal;Lewis-Sumner syndrome;Lhermitte's sign;Lichen planopilaris;Lichen planus;Lichen sclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver function test abnormal;Liver function test decreased;Liver function test increased;Liver induration;Liver injury;Liver iron concentration abnormal;Liver iron concentration

increased;Liver opacity;Liver palpable;Liver sarcoidosis;Liver scan abnormal;Liver tenderness;Low birth weight baby;Lower respiratory tract herpes infection;Lower respiratory tract infection;Lower respiratory tract infection viral;Lung abscess;Lupoid hepatic cirrhosis;Lupus cystitis;Lupus encephalitis;Lupus endocarditis;Lupus enteritis;Lupus hepatitis;Lupus myocarditis;Lupus myositis;Lupus nephritis;Lupus pancreatitis;Lupus pleurisy;Lupus pneumonitis;Lupus vasculitis;Lupus-like syndrome;Lymphocytic hypophysitis;Lymphocytopenia neonatal;Lymphopenia;MAGIC syndrome;Magnetic resonance imaging liver abnormal;Magnetic resonance proton density fat fraction measurement;Mahler sign;Manufacturing laboratory analytical testing issue;Manufacturing materials issue;Manufacturing production issue;Marburg's variant multiple sclerosis;Marchiafava-Bignami disease;Marine Lenhart syndrome;Mastocytic enterocolitis;Maternal exposure during pregnancy;Medical device site thrombosis;Medical device site vasculitis;MELAS syndrome;Meningitis;Meningitis aseptic;Meningitis herpes;Meningoencephalitis herpes simplex neonatal;Meningoencephalitis herpetic;Meningomyelitis herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV test positive;Mesangioproliferative glomerulonephritis;Mesenteric artery embolism;Mesenteric artery thrombosis;Mesenteric vein thrombosis;Metapneumovirus infection;Metastatic cutaneous Crohn's disease;Metastatic pulmonary embolism;Microangiopathy;Microembolism;Microscopic polyangiitis;Middle East respiratory syndrome;Migraine-triggered seizure;Miliary pneumonia;Miller Fisher syndrome;Mitochondrial aspartate aminotransferase increased;Mixed connective tissue disease;Model for end stage liver disease score abnormal;Model for end stage liver disease score increased;Molar ratio of total branched-chain amino acid to tyrosine;Molybdenum cofactor deficiency;Monocytopenia;Mononeuritis;Mononeuropathy multiplex;Morphoea;Morvan syndrome;Mouth swelling;Moyamoya disease;Multifocal motor neuropathy;Multiple organ dysfunction syndrome;Multiple sclerosis;Multiple sclerosis relapse;Multiple sclerosis relapse prophylaxis;Multiple subpial transection;Multisystem inflammatory syndrome in children;Muscular sarcoidosis;Myasthenia gravis;Myasthenia gravis crisis;Myasthenia gravis neonatal;Myasthenic syndrome;Myelitis;Myelitis transverse;Myocardial infarction;Myocarditis;Myocarditis post infection;Myoclonic epilepsy;Myoclonic epilepsy and ragged-red fibres;Myokymia;Myositis;Narcolepsy;Nasal herpes;Nasal obstruction;Necrotising herpetic retinopathy;Neonatal Crohn's disease;Neonatal epileptic seizure;Neonatal lupus erythematosus;Neonatal mucocutaneous herpes simplex;Neonatal pneumonia;Neonatal seizure;Nephritis;Nephrogenic systemic fibrosis;Neuralgic amyotrophy;Neuritis;Neuritis cranial;Neuromyelitis optica pseudo relapse;Neuromyelitis optica spectrum disorder;Neuromyotonia;Neuronal neuropathy;Neuropathy peripheral;Neuropathy, ataxia, retinitis pigmentosa syndrome;Neuropsychiatric lupus;Neurosarcoidosis;Neutropenia;Neutropenia neonatal;Neutropenic colitis;Neutropenic infection;Neutropenic sepsis;Nodular rash;Nodular vasculitis;Noninfectious myelitis;Noninfective encephalitis;Noninfective encephalomyelitis;Noninfective oophoritis;Obstetrical pulmonary embolism;Occupational exposure to communicable disease;Occupational exposure to SARS-CoV-2;Ocular hyperaemia;Ocular myasthenia;Ocular pemphigoid;Ocular sarcoidosis;Ocular vasculitis;Oculofacial paralysis;Oedema;Oedema blister;Oedema due to hepatic disease;Oedema mouth;Oesophageal achalasia;Ophthalmic artery thrombosis;Ophthalmic herpes simplex;Ophthalmic herpes zoster;Ophthalmic vein thrombosis;Optic neuritis;Optic

neuropathy;Optic perineuritis;Oral herpes;Oral lichen planus;Oropharyngeal oedema;Oropharyngeal spasm;Oropharyngeal swelling;Osmotic demyelination syndrome;Ovarian vein thrombosis;Overlap syndrome;Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection;Paget-Schroetter syndrome;Palindromic rheumatism;Palisaded neutrophilic granulomatous dermatitis;Palmoplantar keratoderma;Palpable purpura;Pancreatitis;Panencephalitis;Papillophlebitis;Paracancerous pneumonia;Paradoxical embolism;Parainfluenzae viral laryngotracheobronchitis;Paraneoplastic dermatomyositis;Paraneoplastic pemphigus;Paraneoplastic thrombosis;Paresis cranial nerve;Parietal cell antibody positive;Paroxysmal nocturnal haemoglobinuria;Partial seizures;Partial seizures with secondary generalisation;Patient isolation;Pelvic venous thrombosis;Pemphigoid;Pemphigus;Penile vein thrombosis;Pericarditis;Pericarditis lupus;Perihepatic discomfort;Periorbital oedema;Periorbital swelling;Peripheral artery thrombosis;Peripheral embolism;Peripheral ischaemia;Peripheral vein thrombus extension;Periportal oedema;Peritoneal fluid protein abnormal;Peritoneal fluid protein decreased;Peritoneal fluid protein increased;Peritonitis lupus;Pernicious anaemia;Petit mal epilepsy;Pharyngeal oedema;Pharyngeal swelling;Pityriasis lichenoides et varioliformis acuta;Placenta praevia;Pleuroparenchymal fibroelastosis;Pneumobilia;Pneumonia;Pneumonia adenoviral;Pneumonia cytomegaloviral;Pneumonia herpes viral;Pneumonia influenzal;Pneumonia measles;Pneumonia mycoplasmal;Pneumonia necrotising;Pneumonia parainfluenzae viral;Pneumonia respiratory syncytial viral;Pneumonia viral;POEMS syndrome;Polyarteritis nodosa;Polyarthritis;Polychondritis;Polyglandular autoimmune syndrome type I;Polyglandular autoimmune syndrome type II;Polyglandular autoimmune syndrome type III;Polyglandular disorder;Polymicrogyria;Polymyalgia rheumatica;Polymyositis;Polyneuropathy;Polyneuropathy idiopathic progressive;Portal pyaemia;Portal vein embolism;Portal vein flow decreased;Portal vein pressure increased;Portal vein thrombosis;Portosplenomesenteric venous thrombosis;Post procedural hypotension;Post procedural pneumonia;Post procedural pulmonary embolism;Post stroke epilepsy;Post stroke seizure;Post thrombotic retinopathy;Post thrombotic syndrome;Post viral fatigue syndrome;Postictal headache;Postictal paralysis;Postictal psychosis;Postictal state;Postoperative respiratory distress;Postoperative respiratory failure;Postoperative thrombosis;Postpartum thrombosis;Postpartum venous thrombosis;Postpericardiotomy syndrome;Post-traumatic epilepsy;Postural orthostatic tachycardia syndrome;Precerebral artery thrombosis;Pre-eclampsia;Preictal state;Premature labour;Premature menopause;Primary amyloidosis;Primary biliary cholangitis;Primary progressive multiple sclerosis;Procedural shock;Proctitis herpes;Proctitis ulcerative;Product availability issue;Product distribution issue;Product supply issue;Progressive facial hemiatrophy;Progressive multifocal leukoencephalopathy;Progressive multiple sclerosis;Progressive relapsing multiple sclerosis;Prosthetic cardiac valve thrombosis;Pruritus;Pruritus allergic;Pseudovasculitis;Psoriasis;Psoriatic arthropathy;Pulmonary amyloidosis;Pulmonary artery thrombosis;Pulmonary embolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary microemboli;Pulmonary oil microembolism;Pulmonary renal syndrome;Pulmonary sarcoidosis;Pulmonary sepsis;Pulmonary thrombosis;Pulmonary tumour thrombotic microangiopathy;Pulmonary vasculitis;Pulmonary veno-occlusive disease;Pulmonary venous thrombosis;Pyoderma gangrenosum;Pyostomatitis vegetans;Pyrexia;Quarantine;Radiation leukopenia;Radiculitis

brachial;Radiologically isolated syndrome;Rash;Rash erythematous;Rash pruritic;Rasmussen encephalitis;Raynaud's phenomenon;Reactive capillary endothelial proliferation;Relapsing multiple sclerosis;Relapsing-remitting multiple sclerosis;Renal amyloidosis;Renal arteritis;Renal artery thrombosis;Renal embolism;Renal failure;Renal vascular thrombosis;Renal vasculitis;Renal vein embolism;Renal vein thrombosis;Respiratory arrest;Respiratory disorder;Respiratory distress;Respiratory failure;Respiratory paralysis;Respiratory syncytial virus bronchiolitis;Respiratory syncytial virus bronchitis;Retinal artery embolism;Retinal artery occlusion;Retinal artery thrombosis;Retinal vascular thrombosis;Retinal vasculitis;Retinal vein occlusion;Retinal vein thrombosis;Retinol binding protein decreased;Retinopathy;Retrograde portal vein flow;Retroperitoneal fibrosis;Reversible airways obstruction;Reynold's syndrome;Rheumatic brain disease;Rheumatic disorder;Rheumatoid arthritis;Rheumatoid factor increased;Rheumatoid factor positive;Rheumatoid factor quantitative increased;Rheumatoid lung;Rheumatoid neutrophilic dermatosis;Rheumatoid nodule;Rheumatoid nodule removal;Rheumatoid scleritis;Rheumatoid vasculitis;Saccadic eye movement;SAPHO syndrome;Sarcoidosis;SARS-CoV-1 test;SARS-CoV-1 test negative;SARS-CoV-1 test positive;SARS-CoV-2 antibody test;SARS-CoV-2 antibody test negative;SARS-CoV-2 antibody test positive;SARS-CoV-2 carrier;SARS-CoV-2 sepsis;SARS-CoV-2 test;SARS-CoV-2 test false negative;SARS-CoV-2 test false positive;SARS-CoV-2 test negative;SARS-CoV-2 test positive;SARS-CoV-2 viraemia;Satoyoshi syndrome;Schizencephaly;Scleritis;Sclerodactylia;Scleroderma;Scleroderma associated digital ulcer;Scleroderma renal crisis;Scleroderma-like reaction;Secondary amyloidosis;Secondary cerebellar degeneration;Secondary progressive multiple sclerosis;Segmented hyalinising vasculitis;Seizure;Seizure anoxic;Seizure cluster;Seizure like phenomena;Seizure prophylaxis;Sensation of foreign body;Septic embolus;Septic pulmonary embolism;Severe acute respiratory syndrome;Severe myoclonic epilepsy of infancy;Shock;Shock symptom;Shrinking lung syndrome;Shunt thrombosis;Silent thyroiditis;Simple partial seizures;Sjogren's syndrome;Skin swelling;SLE arthritis;Smooth muscle antibody positive;Sneezing;Spinal artery embolism;Spinal artery thrombosis;Splenic artery thrombosis;Splenic embolism;Splenic thrombosis;Splenic vein thrombosis;Spondylitis;Spondyloarthropathy;Spontaneous heparin-induced thrombocytopenia syndrome;Status epilepticus;Stevens-Johnson syndrome;Stiff leg syndrome;Stiff person syndrome;Stillbirth;Still's disease;Stoma site thrombosis;Stoma site vasculitis;Stress cardiomyopathy;Stridor;Subacute cutaneous lupus erythematosus;Subacute endocarditis;Subacute inflammatory demyelinating polyneuropathy;Subclavian artery embolism;Subclavian artery thrombosis;Subclavian vein thrombosis;Sudden unexplained death in epilepsy;Superior sagittal sinus thrombosis;Susac's syndrome;Suspected COVID-19;Swelling;Swelling face;Swelling of eyelid;Swollen tongue;Sympathetic ophthalmia;Systemic lupus erythematosus;Systemic lupus erythematosus disease activity index abnormal;Systemic lupus erythematosus disease activity index decreased;Systemic lupus erythematosus disease activity index increased;Systemic lupus erythematosus rash;Systemic scleroderma;Systemic sclerosis pulmonary;Tachycardia;Tachypnoea;Takayasu's arteritis;Temporal lobe epilepsy;Terminal ileitis;Testicular autoimmunity;Throat tightness;Thromboangiitis obliterans;Thrombocytopenia;Thrombocytopenic purpura;Thrombophlebitis;Thrombophlebitis migrans;Thrombophlebitis

neonatal;Thrombophlebitis septic;Thrombophlebitis superficial;Thromboplastin antibody positive;Thrombosis;Thrombosis corpora cavernosa;Thrombosis in device;Thrombosis mesenteric vessel;Thrombotic cerebral infarction;Thrombotic microangiopathy;Thrombotic stroke;Thrombotic thrombocytopenic purpura;Thyroid disorder;Thyroid stimulating immunoglobulin increased;Thyroiditis;Tongue amyloidosis;Tongue biting;Tongue oedema;Tonic clonic movements;Tonic convulsion;Tonic posturing;Topectomy;Total bile acids increased;Toxic epidermal necrolysis;Toxic leukoencephalopathy;Toxic oil syndrome;Tracheal obstruction;Tracheal oedema;Tracheobronchitis;Tracheobronchitis mycoplasmal;Tracheobronchitis viral;Transaminases abnormal;Transaminases increased;Transfusion-related alloimmune neutropenia;Transient epileptic amnesia;Transverse sinus thrombosis;Trigeminal nerve paresis;Trigeminal neuralgia;Trigeminal palsy;Truncus coeliacus thrombosis;Tuberous sclerosis complex;Tubulointerstitial nephritis and uveitis syndrome;Tumefactive multiple sclerosis;Tumour embolism;Tumour thrombosis;Type 1 diabetes mellitus;Type I hypersensitivity;Type III immune complex mediated reaction;Uhthoff's phenomenon;Ulcerative keratitis;Ultrasound liver abnormal;Umbilical cord thrombosis;Uncinate fits;Undifferentiated connective tissue disease;Upper airway obstruction;Urine bilirubin increased;Urobilinogen urine decreased;Urobilinogen urine increased;Urticaria;Urticaria papular;Urticular vasculitis;Uterine rupture;Uveitis;Vaccination site thrombosis;Vaccination site vasculitis;Vagus nerve paralysis;Varicella;Varicella keratitis;Varicella post vaccine;Varicella zoster gastritis;Varicella zoster oesophagitis;Varicella zoster pneumonia;Varicella zoster sepsis;Varicella zoster virus infection;Vasa praevia;Vascular graft thrombosis;Vascular pseudoaneurysm thrombosis;Vascular purpura;Vascular stent thrombosis;Vasculitic rash;Vasculitic ulcer;Vasculitis;Vasculitis gastrointestinal;Vasculitis necrotising;Vena cava embolism;Vena cava thrombosis;Venous intravasation;Venous recanalisation;Venous thrombosis;Venous thrombosis in pregnancy;Venous thrombosis limb;Venous thrombosis neonatal;Vertebral artery thrombosis;Vessel puncture site thrombosis;Visceral venous thrombosis;VIth nerve paralysis;VIth nerve paresis;Vitiligo;Vocal cord paralysis;Vocal cord paresis;Vogt-Koyanagi-Harada disease;Warm type haemolytic anaemia;Wheezing;White nipple sign;XIth nerve paralysis;X-ray hepatobiliary abnormal;Young's syndrome;Zika virus associated Guillain Barre syndrome.

```

*****
** Program Name   : adc19ef-ve-cov-7pd2-wo-eval.sas           **
** Date Created  : 22Mar2021                                 **
** Programmer Name : WUY169                                  **
** Purpose       : Create adc19ef-ve-cov-7pd2-wo-eval       **
** Input data    : adc19ef                                   **
** Output data   : adc19ef-ve-cov-7pd2-wo-eval.html         **
*****
options mprint mlogic symbolgen mprint symbolgen mlogic nocenter missing=" ";
title;
footnote;

proc datasets library=WORK kill nolist nodetails;
quit;

%let prot=/Volumes/app/cdars/prod/sites/cdars4/prjC459/nda2_unblinded_esub/bla_esub_adam/saseng/cdisc3_0;
libname datvprot "&prot./data_vai" access=readonly;

%let codename=adc19ef-ve-cov-7pd2-wo-eval;
%let outlog=&prot./analysis/esub/logs/&codename..log;
%let outtable=&prot./analysis/esub/output/&codename..html;

/* proc printto log="&outlog" new; */
/* run; */

/**** Population Flag ****/

proc sql;
  create table popf as select distinct usubjid, evaleffl, trt01pn, trt01p, aai2effl
  from datvprot.adsl
  where EVALEFFL='Y' and MULENRFL ne "Y" and PHASEN ne 1 and HIVFL = 'N'
  order by usubjid;
quit;

proc sql;
  create table adc19ef as select *
  from datvprot.adc19ef
  order by usubjid;
quit;

data tpop;
  merge adc19ef (in = a) popf (in = b);
  by usubjid;
  if a*b;
run;

/***** Total Population *****/

proc sql;
  create table dsin as select distinct subjid, trt01pn, trt01p, paramn, paramcd, param, CDCRMUFL, CDP27FL,
PDRMUPFL,
  aval, avalc, evaleffl, PDP27FL, pdrmufll, IILD27FL, filocrfl, usubjid, aai2effl, PDP214FL, IILD214FL, CDRMUPFL,
adt, dvsttdt

```

```
from tpop;
quit;
```

```
proc sql noprint;
  select bign into :n1 - :n2
  from (select count(distinct usubjid) as bign, trt01pn
  from dsin
  where PDP27FL = "Y"
  group by trt01pn)
  order by trt01pn;
quit;
```

```
%let n1 = &n1.;
%let n2 = &n2.;
```

```
%put &n1 &n2.;
```

```
/***/ Subjects at Risk ***/
```

```
proc sql;
  create table riskp as select distinct usubjid, trt01pn, trt01p, aval
  from dsin
  where PDRMUPFL = "N" and PDP27FL = "Y" and paramcd in ("ST27PD") and aval > 0;
quit;
```

```
proc sql;
  create table n2 as select count(distinct usubjid) as n2, trt01pn
  from riskp
  group by trt01pn
  order by trt01pn;
quit;
```

```
***** Events (n1) ***/
```

```
proc sql;
  create table evnts as select distinct usubjid, param, avalc, trt01pn
  from dsin
  where paramcd in ("C19ONST") and upcase(ILD27FL) = "Y" and upcase(FILOCRFL) = "Y" and ((not
  missing(DVSTDT) and adt <= DVSTDT) or missing(DVSTDT))
  and usubjid in (select distinct usubjid from riskp)
  order by usubjid;
quit;
```

```
proc sql;
  create table evtN as select count(distinct usubjid) as smln, trt01pn
  from evnts
  group by trt01pn
  order by trt01pn;
quit;
```

```
***** Make sure All treatment arms are present in EVTN dataset (with 0 cases) ***/
```

```
proc sql noprint;
  create table trt_u as
  select distinct trt01pn
```

```
from dsin
order by trt01pn;
quit;
```

```
data evtn;
merge evtn (in=a) trt_u (in=b);
by trt01pn;
if b;
if missing(smln) then smln = 0;
run;
```

```
/**/ Surveillance Time /**/
```

```
proc sql;
create table st as select distinct usubjid, aval, trt01pn, trt01p, paramcd
from dsin
where paramcd in ("ST27PD") and
usubjid in (select distinct usubjid from riskp);
quit;
```

```
proc sql;
create table riskn as select a.*, b.ptyrs, pty
from n2 a inner join
(select (sum(aval)/365.25/1000) as ptyrs, sum(aval)/365.25 as pty, trt01pn
from st group by trt01pn) b on a.trt01pn = b.trt01pn;
quit;
```

```
proc sql;
create table pt as select strip(put(a.smln,best.)) as evtn, b.*, smln/ptyrs as ir,
a.smln, (put(ptyrs, 7.3) || " (" || strip(put(n2,best.)) || ")") as ptyb
from evtn a inner join
riskn b on a.trt01pn = b.trt01pn;
quit;
```

```
/**/ Total cases /**/
```

```
proc sql noprint;
select sum(smln) into :ncases
from pt;
quit;
```

```
%let ncases = &ncases.;
```

```
/**/ Cases in Vaccination Group /**/
```

```
proc sql noprint;
select smln into :nv1-:nv2 from pt;
quit;
```

```
%let nv1 = &nv1;
```

```
%let nv2 = &nv2;
```

```
%let ncases = &ncases;
```

```
%let ve = 0.3;
```

```
%put No. of Cases in Vaccination group are &nv1.;
```



```
%put Total No. of Cases in the trial are &ncases.;
```

```
proc transpose data = pt out = tr prefix = trt;  
  var ptyrs;  
  id trt01pn;  
run;
```

```
data tr;  
  set tr;  
  *IRR=trt8/trt9;  
  n_p = &ncases - &nv1.;  
  r = trt8/trt9;  
  P = R*(1-&VE)/(1+R*(1-&VE));  
  IR_V=&nv1/trt8;  
  IR_P=n_p/trt9;  
  alpha = 0.05;  
  length VE lcl ucl $25.;  
  VE=strip(put(100*(1-IR_V/IR_P),7.1));  
  pr = put(CDF('BETA',p,0.700102+&nv1,1+&ncases-&nv1),7.4);  
  pr_n = CDF('BETA',p,0.700102+&nv1,1+&ncases-&nv1);  
  qh_theta = quantile('BETA',0.975,0.700102+&nv1,1+&ncases-&nv1);  
  ql_theta = quantile('BETA',0.025,0.700102+&nv1,1+&ncases-&nv1);  
  QH = round (100*(R - ql_theta*(R+1))/(R*(1-ql_theta)), 0.01);  
  QL = round (100*(R - qh_theta*(R+1))/(R*(1-qh_theta)), 0.01);
```

```
*** Use Clopper-Pearson Method to display CI ****;
```

```
fu = finv( 1- alpha/2, 2*(&nv1.+1), 2*N_P);  
ucl_pi = (&nv1 +1)*fu/(N_P + (&nv1.+1)*fu);  
fl = finv(1-alpha/2, 2*(N_P+1), 2*&nv1.);  
if &nv1 = 0 then lcl_pi = 0;  
else lcl_pi = &nv1./(&nv1. + fl*(N_P+1));  
ucl_theta = ucl_pi/(r*(1-ucl_pi));  
lcl_theta = lcl_pi/(r*(1-lcl_pi));  
qu = 100*(1 - lcl_theta);  
ql = 100*(1 - ucl_theta);  
if not missing(ql) then lcl = strip(put(ql,8.1));  
else lcl = "-(*ESC*){unicode 221e}";  
if not missing(qu) then ucl = strip(put(qu,8.1));  
else ucl = 'NE';  
vci = "(" || strip(lcl) || ", " || strip(ucl) || " )";  
**** END ****;
```

```
text = "First COVID-19 occurrence from 7 days after Dose 2";  
/**** If probability is 0 then show <0.0001' and if its 1 then then show >0.9999 *****/  
if pr_n < 0.0001 then pr = '<0.0001';  
else if pr_n > 0.9999 then pr = '>0.9999';  
/**** If VE is missing then show Infinity symbol *****/  
if strip(ve) = '.' then do; ve = "-(*ESC*){unicode 221e}"; vci = "(NA, NA)"; end;  
run;
```

```
proc transpose data = pt out = trn prefix = trtn;  
  var evtN;  
  id trt01pn;  
run;
```

```

proc transpose data = pt out = try prefix = trty;
  var ptyb;
  id trt01pn;
run;

proc sql;
  create table final as select a.*, b.*, c.*
  from trn (drop = _name_) a,
  try (drop = _name_) b,
  tr (drop = _name_) c;
quit;

***** Set up Report *****;
ods escapechar="~";

/* ods html file="&outtable."; */

title1 "Vaccine Efficacy (*ESC*){unicode 2013} First COVID-19 Occurrence From 7 Days After Dose 2";
title2 "(*ESC*){unicode 2013} Blinded Placebo-Controlled Follow-up Period";
title3 "(*ESC*){unicode 2013} Subjects Without Evidence of Infection Prior to 7 Days After Dose 2 (*ESC*){unicode 2013} Evaluable Efficacy (7 Days) Population";
footnote1 "Abbreviations: N-binding = SARS-CoV-2 nucleoprotein(*ESC*){unicode 2013}binding; NAAT = nucleic acid amplification test; ~nSARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; VE = vaccine efficacy.";
footnote2 "Note: Subjects who had no serological or virological evidence (prior to 7 days after receipt of the last dose) of past SARS-CoV-2 infection (ie, N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2), and had negative NAAT (nasal swab) at any unscheduled visit prior to 7 days after Dose 2 were included in the analysis.";
footnote3 "a.(*ESC*){nbspspace 5}N = number of subjects in the specified group. ~nb.(*ESC*){nbspspace 5}n1 = Number of subjects meeting the endpoint definition.";
footnote4 "c.(*ESC*){nbspspace 5}Total surveillance time in 1000 person-years for the given endpoint across all subjects within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.";
footnote5 "d.(*ESC*){nbspspace 5}n2 = Number of subjects at risk for the endpoint.";
footnote6 "e.(*ESC*){nbspspace 5}Confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted for surveillance time.";
footnote7 "f.(*ESC*){nbspspace 5}Posterior probability (Pr) was calculated using a beta-binomial model with prior beta (0.700102, 1) adjusted for surveillance time. Refer to the statistical analysis plan, Appendix 2, for more details.";
;

proc report data = final nowd headline headskip split = "*" style(report)=[];
column (text ("Vaccine Group (as Randomized)~{line}" ("BNT162b2 (30 ~{unicode 03BC}g)*(N~{super a})=&n1.)"
trtn8 trty8) ("Placebo*(N~{super a})=&n2.)" trtn9 trty9)) ve vci pr);
define text / "Efficacy Endpoint" flow style(header)=[just=1] style(column)=[cellwidth=3in just=1];
define trtn8 / " n1~{super b}" style(column)=[cellwidth=0.8in just=c];
define trty8 / "Surveillance*Time~{super c} (n2~{super d})" style(column)=[cellwidth=1.5in just=c];
define trtn9 / " n1~{super b}" style(column)=[cellwidth=0.8in just=c];
define trty9 / "Surveillance*Time~{super c} (n2~{super d})" style(column)=[cellwidth=1.5in just=c];
define ve / " VE (%)" style(column)=[cellwidth=0.5in just=c];
define vci / " (95% CI~{super e})" style(column)=[cellwidth=0.5in just=c];
define pr / "Pr (VE >30% | data)~{super f}" style(column)=[cellwidth=0.5in just=c];
run;

ods HTML close;

```

```
proc printto;  
run;
```